Coronavirus: diagnosis and therapy in humans

EXPANDING AND IMPROVING NANOBODY REPERTOIRES: TARGETING SARS-COV-2

Absstract of: WO2024178232A2

Provided are anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) VHH antibodies, and methods of making and using the VHH chain antibodies.

SARS-CoV-2 NEUTRALIZING ANTIBODIES

Absstract of: WO2024175802A2

The present invention relates to antibodies or antigen-binding fragments thereof against SARS- related coronavirus, pharmaceutical compositions comprising such antibodies or antigen-binding fragments thereof, kits comprising such antibodies or antigen-binding fragments thereof, and the antibodies or antigen-binding fragments thereof, the pharmaceutical compositions and the kits for use as a medicament, and in the treatment or prevention of a disease caused by SARS-related coronavirus. The present invention further relates to methods of treating, preventing or reducing the severity of an infection with a SARS-related coronavirus, and to nucleic acids encoding such antibodies or antigen-binding fragments thereof, expression vectors comprising such nucleic acids, host cells comprising such nucleic acids or expression vectors, and methods for the production of such antibodies or antigen-binding fragments thereof.

MULTICISTRONIC VACCINE AND METHODS FOR PRODUCING AND USING THE SAME

Absstract of: WO2024178371A1

The present disclosure provides multi ci str onic vaccines and method for producing and using the same in preventing infection or transmission, or reducing severity of disease caused by influenza and/or SARS-Cov-2 virus in a subject. Multicistronic vaccines of the disclosure can be administered via intramuscular, intranasal, or inhalation route. In one particular embodiments, the disclosure provides a recombinant adenovirus comprising at least two different extraneous oligonucleotides that are capable of stimulating an immune response in a subject. Each of the oligonucleotide independently comprises an oligonucleotide that encodes either influenza or SARS-Cov-2 virus antigens.

ADJUVANTED PROTEIN VACCINES COMPRISING MODIFIED FULL-LENGTH SPIKE PROTEIN OF SARS-COV-2 COMPOSITION AND METHODS OF USE

Absstract of: WO2024177672A1

Disclosed herein are adjuvanted protein vaccines comprising: a non-phospholipid liposome and one or more proteins, wherein the protein is encapsulated within the non- phospholipid liposome, and wherein the protein is selected from: (i) a modified full-length spike protein that generates IgG antibody responses for 120 days after two injections of the adjuvanted protein vaccine, by subcutaneous or intramuscular routes; (ii) a modified spike protein sequence of a coronavirus; (iii) a protein sequence from a coronavirus; and (iv) a protein from an infectious agent that generates IgG antibody responses to proteins after one or two subcutaneous or intramuscular injections. Also disclose herein are modified spike protein sequence containing a modified full-length SARS-CoV-2 spike protein sequence. Methods of use of the vaccines and sequences are also disclosed herein.

EG017 OINTMENT

Absstract of: WO2024174962A1

The present invention provides an EG017 semi-solid formulation. By means of adjustment of the type of a fat-soluble matrix, addition of an antibacterial agent, and optimization of a preparation process, the EG017 semi-solid formulation (such as an ointment) can be administrated in an external application mode to treat and/or prevent eye symptoms caused by xerophthalmia, corneal injury and SARS-CoV-2, solving the problem in the prior art of topical administration of EG017 to eyes leading to no noticeable effect.

BISPECIFIC ANTIBODY FOR BROAD-SPECTRUM NOVEL CORONAVIRUS

Absstract of: WO2024174595A1

The present invention provides a bispecific antibody for a broad-spectrum novel coronavirus. The bispecific antibody of the present invention comprises a first targeting domain D1, which targets a first epitope of a SARS-CoV-2RBD domain; and a second targeting domain D2, which targets a second epitope of the SARS-CoV-2RBD domain. The bispecific antibody of the present invention has broad-spectrum neutralizing activity, can effectively neutralize SARS‐CoV‐2 and a variety of SARS‐CoV‐2 novel coronavirus variants having strong infectivity and high harmfulness, and therefore has great application value in prevention, treatment and/or detection of novel coronavirus infection.

PREPARATION METHOD AND APPLICATION OF ULTRA-RAPID AND HIGH-SENSITIVITY MULTICHANNEL NOVEL CORONAVIRUS NUCLEIC ACID RAMAN ANALYSIS CHIP

Absstract of: WO2024174565A1

A preparation method for a multichannel novel coronavirus nucleic acid Raman analysis chip. Firstly, by using a semiconductor nanomaterial self-assembly method, an SERS substrate is constructed on the surface of a hydrophilic substrate as a signal amplification unit; secondly, according to the nucleic acid sequence of a target strain of novel coronavirus, a plurality of virus nucleic acid recognition units having a single base recognition capability are synthesized; thirdly, by using a Raman signal molecule PTCDA as a signal response unit and using TCNQ as a signal reference unit, a ratiometric Raman signal is constructed as a signal output unit for nucleic acid test, so that a rapid novel coronavirus nucleic acid Raman analysis probe is constructed, wherein the probe contains no enzyme and is free of a nucleic acid amplification process; and finally, analysis probes are spatially arranged in sequence for the nucleic acid sequences of different novel coronavirus variant strains, to prepare a multichannel novel coronavirus nucleic acid Raman analysis chip.

METHODS FOR TREATING INFLAMMATORY AND/OR AUTOIMMUNE SYMPTOMS ASSOCIATED WITH BIOLOGIC AND/OR mRNA VACCINE ADMINISTRATION

Absstract of: WO2024176194A1

Methods for treating inflammatory, autoinflammatory or autoimmune symptoms associated with administration of a biologic (e.g., a vaccine) are described herein. Certain methods include treating side effects of mRNA based vaccines such as COVID-19 vaccines.

IMMUNOGENIC COMPOSITION, USE THEREOF AND PROCESS OF OBTAINING A COMBINED IMMUNOGENIC COMPOSITION AGAINST COVID-19 AND SEASONAL INFLUENZA

Absstract of: WO2024174012A1

The present invention relates to an immunogenic composition that comprises (i) antigens of the inactivated Newcastle virus (NDV) expressing a stabilized form of the spike antigen (HXP-S) of SARS-CoV-2 (NDV-HXP-S); and (ii) antigens of the trivalent vaccine for seasonal influenza, the composition optionally also comprising an adjuvant. Furthermore, the present invention relates to the use of said immunogenic composition for producing a combined vaccine against COVID-19 and seasonal influenza. Additionally, the present invention relates to a method for obtaining said combined vaccine that comprises the following steps: (a) producing the virus and NDV-HXP-S antigen on an industrial scale using the same factory as that used for producing a monovalent seasonal influenza vaccine; (b) producing the monovalent seasonal influenza vaccine; and (c) combining the antigen compositions of steps "a" and "b" with an acceptable pharmaceutical vehicle to create the combined vaccine.

MICROWAVE DISINFECTION PROTOCOL OPTIMISED FOR THE DESTRUCTION/ INACTIVATION OF SARS-COV-2 AND H1N1 VIRUSES

Absstract of: AU2023225212A1

The invention concerns a microwave disinfection device ( 2 ) configured to destroy/ inactivate the SARS-CoV-2 and H1N1 viruses and comprising a microwave irradiation section ( 22 ) configured to : irradiate microwave signals that have an incident electric field amplitude not higher than 6 V/m and frequencies that are included in the 8-10 GHz band and are spaced from each other by a step comprised between 10 MHz and 100 MHz; irradiate the microwave signals at each individual frequency for a time interval comprised between 50 ms and 1 s; and irradiate the microwave signals with duty cycles comprised between 5% and 50%.

ALZ-801 FOR USE IN TREATING A COVID-19 ASSOCIATED NEUROLOGICAL SYMPTOM

Absstract of: AU2023215421A1

Provided herein are methods for reducing p-tau, Abeta40, Abeta42, and/or the p-tau/Abeta42 ratio in subjects using ALZ-801. Also provided are methods of treating conditions associated with elevated levels of p-tau, elevated levels of Abeta40, elevated levels of Abeta42, and/or an elevated p-tau/Abeta42 ratio.

METHODS FOR TREATING INFLAMMATORY AND/OR AUTOIMMUNE SYMPTOMS ASSOCIATED WITH BIOLOGIC AND/OR MRNA VACCINE ADMINISTRATION

Absstract of: US2024285655A1

Methods for treating inflammatory, autoinflammatory or autoimmune symptoms associated with administration of a biologic (e.g., a vaccine) are described herein. Certain methods include treating side effects of mRNA based vaccines such as COVID-19 vaccines.

COMPOUNDS FOR THE TREATMENT OF SARS

Absstract of: US2024285598A1

Disclosed are bis-amide inhibitors of SARS-CoV-2 (CO VID), and methods of using them to treat a severe acute respiratory syndrome.

METHODS OF USING PROBENECID FOR TREATMENT OF CORONAVIRUS INFECTIONS

Absstract of: US2024285561A1

Compositions and methods of treating a subject for a coronavirus infection are provided. The methods typically include administering the subject an effective amount of probenecid, a metabolite or anaolg thereof, or a pharmaceutically acceptable salt thereof. The methods can by therapeutic and/or prophylactic. The amount of probenecid or a pharmaceutically acceptable salt thereof can be effective to, for example, reduce viral replication, reduce one or more symptoms of disease, disorder, or illness associated with virus, or a combination thereof. In preferred embodiments, the virus is a Severe acute respiratory syndrome-related coronavirus such as SARS-CoV-2 or SARS-CoV, a Middle East respiratory syndrome-related coronavirus such as MERS-CoV, or a coronavirus that causes the common cold.

PHARMACEUTICAL COMPOSITION COMPRISING LIPASE INHIBITOR FOR TREATMENT OR TREATMENT OF RNA VIRAL INFECTIONS

Absstract of: US2024285557A1

The present invention relates to a therapeutic agent of a lipase inhibitor for a wide spectrum of RNA viral infections in humans and animals. More specifically, the lipase inhibitor can be used as a therapeutic agent for influenza A virus infection, bovine coronavirus infection, porcine epidemic diarrhea coronavirus infection, bovine rotavirus infection, porcine reproductive and respiratory syndrome virus infection, and sapoviral infection and furthermore, can be utilized as a therapeutic agent for various RNA viral infections in humans and animals, such as infections with SARS COV-1, MERS-COV, Zika virus, dengue fever virus, and hepatitis A and C viruses.

COMPOSITIONS FOR AND METHODS OF INHIBITING SARS-COV-2 INFECTION

Absstract of: US2024285552A1

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the etiological agent for coronavirus disease 2019 (COVID-19), has emerged as an ongoing global pandemic. Presently, there are no clinically approved vaccines nor drugs for COVID-19. Hence, there is an urgent need to accelerate the development of effective antivirals. One or more members of the 8-Hydroxyquinoline and Benzylamine structural classes inhibited SARS-CoV-2 infection induced cytopathic effect in vitro, inhibited the exopeptidase activity of angiotensin converting enzyme 2 (ACE2), and disrupted the binding between ACE2 and the Spike protein of SARS-CoV-2. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

SUPER M.E.N.

Absstract of: US2024285002A1

Problem: Masks are particularly needed that provide 100% protection from droplet infection by the novel coronavirus, including the eyes, and must enable clear speech, must not fog up transparent sheets or eyeglasses, must be able to be used by women without removing their makeup, and must be able to be worn for long periods of time.Means of Solving the Problems: The invention is designed to increase rigidity by bending flat transparent sheets to improve temperature and humidity, increase internal temperature and humidity to prevent infiltration by viral particles, completely block viral droplets from contacting the eyes, nose and mouth, exhaust exhaled air to prevent fogging of the transparent sheets and eyeglasses, enable clear conversation, prevent women's makeup from being rubbed off, be able to be put in a pocket, enable eating, and support use as an eye mask. The mask is the world's first so-called face shield and has the best performance and the most applications for the novel coronavirus.

METHODS AND COMPOSITIONS BASED ON LONGITUDINAL STUDIES

Absstract of: US2024288440A1

The present application relates to infectious diseases, pathogenic organisms or pathogenic antigens, and the immune responses that are the body's first line of defense thereto. The application enables medical protocols and products inter alia for treating or preventing or limiting the dissemination of an infectious disease. Methods and compositions are disclosed which employ dIgA for assessing functional immune responses to a pathogen, and in prophylactic or therapeutic compositions. In particular embodiments, the methods and compositions enhance the armamentarium for those charged with managing infectious diseases and populations exposed to highly transmissible and potentially debilitating or fatal pathogens such as those causing epidemics. One particular infectious disease is COVID-19 caused by the virus SARS-COV-2.

ANTIBODY AGAINST NUCLEOCAPSID PROTEIN OF SARS-COV-2

Absstract of: US2024288429A1

The purpose of the present invention is to provide an antibody that enables simple, rapid and sensitive detection of SARS-COV-2, i.e., the causative virus of COVID-19 while suppressing nonspecific reactions, and an immunological detection method and a kit comprising the antibody. By using an antibody that binds to the nucleocapsid protein of SARS-COV-2 or an antibody fragment thereof, in particular, an antibody that recognizes a specific region of the protein or an antibody fragment thereof, provided are a specific and sensitive immunological detection method and kit, in particular, a detection method using a sandwich method such as an immunochromatography method or ELISA method, as well as immunochromatographic test strip containing the antibody and a kit containing the test strip.

ANTIBODY CAPABLE OF BINDING SPECIFICALLY TO NUCLEOCAPSID PROTEIN OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 OR FRAGMENT THEREOF, AND USE OF SAID ANTIBODY OR SAID FRAGMENT

Absstract of: US2024288427A1

Provided are an antibody or fragment thereof specifically bindable to the NTD or CTD of the N protein of SARS-CoV-2, and use of the antibody or fragment thereof. An antibody or fragment thereof specifically bindable to the amino acid sequence of SEQ ID NO: 1 or 2 is disclosed.

MODIFIED PIV5 VACCINE VECTORS: METHODS OF MAKING AND USES

Absstract of: US2024287544A1

A CVB viral expression vector comprising a PIV5 W3A viral genome that contains mutations at amino acid residue S157 or S156 in the P/V gene and a deletion of the small hydrophobic (SH) gene of the PIV5 W3A viral genome, wherein the amino acid substitution at amino acid residue S157 or S156 comprises a substitution of serine (S) to phenylalanine (F) or asparagine (N) and wherein the SH gene has a deletion of the SH open reading frame or a deletion of an entire SH gene transcript unit. The CVB viral expression vector wherein the vector expresses a heterologous polypeptide comprising a SARS-CoV-2 spike (S), and/or nucleocapsid (N) and/or membrane (M) proteins, RSV fusion protein (F) or other antigens.

CIRCULATING LEVELS OF ENDOTHELIAL MICRORNA PREDICT NEW-ONSET DIABETES IN COVID-19 AND LONG COVID

Absstract of: US2024287608A1

Provided herein are compositions and methods for identifying COVID-19 subjects at risk for developing diabetes.

MULTIVALENT ANTI-SPIKE PROTEIN BINDING MOLECULES AND USES THEREOF

Absstract of: US2024287162A1

The present disclosure provides multivalent anti-spike protein binding molecules. The present disclosure further relates to the methods of producing the multivalent anti-spike protein binding molecules, pharmaceutical compositions comprising of the multivalent anti-spike protein binding molecules, and methods of use of the multivalent anti-spike protein binding molecules, e.g., to treat conditions associated with SARS-CoV and SARS-CoV-2 infections, such as COVID-19.

ANTIBODY AGAINST CORONAVIRUS

Absstract of: US2024287161A1

Provided is a human antibody against a spike protein of coronavirus, in particular, against a protein in an extracellular region or a receptor-binding domain.

ETHACRYNIC ACID DERIVATIVES AS INHIBITORS OF MPRO PROTEASE AND SARS-COV-2 REPLICATION

Absstract of: US2024287003A1

A novel compound of formulae (I) or (II), to the use thereof as a drug, particularly for the treatment of SARS-COV-2, for the treatment of COVID-19 disease and any diseases related to beta-coronaviruses, and for the in vitro application thereof in order to study the interaction with Mpro protease.

METHOD AND SYSTEM FOR COMPUTER-AIDED TRACKING OF A PROCEDURE TO BE CARRIED OUT BY A PERSON

Absstract of: US2024290476A1

The disclosure relates to a method and a system for computer-aided tracking of a procedure to be carried out by a person, in particular a production procedure or test procedure, for example for a virus detection test, preferably for carrying out an antigen test for SARS-CoV-2. The disclosure also relates to a method and system for computer-aided validation of a procedure carried out by a person and tracked by computer. The disclosure also relates to a method and system for setting up a person profile for use in one of the aforementioned methods and systems. The disclosure also relates to a computer program product.

AN EPITOPE ORIGINATING FROM SARS-COV-2 N PROTEIN, AN ANTIGEN CONTAINING THE EPITOPE, USES THEREOF AND A METHOD FOR DETECTING DISEASE CAUSED BY CORONAVIRUS

Absstract of: WO2024177525A2

Epitopes originating from SARS-CoV-2 N protein, vaccine antigens specific for SARS-CoV-2 containing the epitopes useful in the treatment or prevention of disease caused by coronavirus as well as a method for detecting disease caused by coronavirus, in particular COVID-19, especially with an acute course, are disclosed.

CRIPPLED CORONAVIRUS: 5'-POLYU TARGETED OLIGO PREVENTS DEVELOPMENT OF INFECTIOUS VIRIONS

Absstract of: WO2024178065A2

The present disclosure provides compositions and methods for treating and detecting coronavirus infection, and in particular, provides compositions and methods for treating and detecting SARS-CoV-2 infection. The present disclosure also relates to the production of compositions for treating and detecting coronavirus infection, and in particular, to the production of compositions for treating and detecting SARS-CoV-2 infection.

PEPTIDES THAT INHIBIT INFECTION BY SARS-COV-2, THE VIRUS THAT CAUSES COVID-19 DISEASE

Absstract of: CA3235784A1

Anti-SARS-CoV-2 ?/?-polypeptides, pharmaceutical compositions containing the same, and methods to inhibit, treat, and ameliorate SARS-CoV-2 infections in mammals, including humans.

PROCYANIDINS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION TRIGGERED BY COVID-19

Absstract of: ZA202213765B

The invention relates to a natural composition for medical purposes and more specifically to a composition comprising procyanidins, for use in the prevention or treatment of endothelial inflammation and/or endothelial systemic dysfunction triggered by Corona virus disease 2019 (COVID-19) including symptomatic post-COVID-19 subjects recovering from COVID-19.

PROTECTION SEQUENCE, PRIMER, PROBE, COMPOSITION AND KIT FOR STEADY-STATE RAPID DETECTION OF NOVEL CORONAVIRUS, AND USE THEREOF AND METHOD THEREFOR

Absstract of: US2024279752A1

The present invention uses a lysis protection solution to treat patient samples, and the samples release genes targeting the 2019-nCoV virus. In the lysis protection solution, multiple target genetic loci are effectively identified by a protection sequence to form a compound, making 2019-nCoV RNA more stable and avoiding extracting purified RNA. The enriched 2019-nCoV RNA compound is further subjected to reverse transcription to obtain cDNA. A signal is then amplified for 40 cycles after the product is identified by a specific 2019-nCoV probe.

PLANT-BASED COMPOSITIONS AND METHODS FOR MODULATION OF INFLAMMATORY RESPONSE POST VIRAL INFECTION

Absstract of: WO2024173473A1

A polyphenol-rich composition is orally administered to alleviate a sign or symptom of a post-viral syndrome, and preferably post-COVID syndrome. Most typically, the composition comprises at least 50 wt% total catechins, at least 20 wt% total chlorogenic acids, and optionally up to 30 wt% total supplemental antioxidants. The composition may be formulated from a green coffee bean extract, a green tea extract, a turmeric extract, a tart cherry or extract thereof, a broccoli or extract thereof, and a kale or extract thereof. Notably, such compositions were effective in individuals post SARS-CoV2 infection to reduce proinflammatory cytokines and interleukins, increase NOHb, and to reduce reactive oxygen species due to mitochondrial dysfunction, iNOS activity, and NOX2 activity.

Self-Amplifying RNA-Based VLP Vaccines

Absstract of: US2024277836A1

The present disclosure provides compositions comprising an sa-RNA VLP vaccine (e.g. the VLP vaccine) that is capable of delivering a self-amplifying RNA to a target cell in a patient, and subsequently elicit an immune response in the patient, which immune response is sufficient to prevent or significantly decrease the duration of an infection by an infectious agent, such as SARS-CoV-2.

TREATMENT OF KNOWN AND UNKNOWN VIRAL INFECTION WITH LIPID AGENTS

Absstract of: US2024277740A1

The present invention provides compositions, systems, kits, and methods for treating a subject with a known or unknown enveloped or non-enveloped viral infection (e.g., an unknown virus, RSV, ADV, SARS-CoV2, CHKV, DENV, HSV-1, HSV-2, EBOV, MARV, ZIKV, or a weaponized virus) by administering or providing a composition comprising a lipid agent selected from: a sulfatide, a sulfatide analog, a ceramide, a lipid moiety comprising a ceramide, a sulfoglycolipid, a sulfogalactolipid, a glycosphingolipid, a seminolipid, or a sphingomyelin. In some embodiments, the compositions reduce lung or systemic inflammation in the subject and/or inhibit viral infection. In certain embodiments, the compositions herein are employed to stop a natural pandemic or a biological attack (e.g., with new or weaponized viruses).

DJUVANTED PROTEIN VACCINES COMPRISING MODIFIED FULL-LENGTH SPIKE PROTEIN OF SARS-COV-2 COMPOSITION AND METHODS OF USE

Absstract of: US2024277832A1

Disclosed herein are adjuvanted protein vaccines comprising: a non-phospholipid liposome and one or more proteins, wherein the protein is encapsulated within the non-phospholipid liposome, and wherein the protein is selected from:(i) a modified full-length spike protein that generates IgG antibody responses for 120 days after two injections of the adjuvanted protein vaccine, by subcutaneous or intramuscular routes;(ii) a modified spike protein sequence of a coronavirus;(iii) a protein sequence from a coronavirus; and(iv) a protein from an infectious agent that generates IgG antibody responses to proteins after one or two subcutaneous or intramuscular injections.Also disclose herein are modified spike protein sequence containing a modified full-length SARS-COV-2 spike protein sequence. Methods of use of the vaccines and sequences are also disclosed herein.

CORONAVIRUS VACCINE

Absstract of: US2024277830A1

The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-COV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.

PHARMACEUTICAL COMPOSITION FOR TREATMENT OF COVID-19 AND RELATED PATHOLOGIES

Absstract of: US2024277826A1

The invention relates to a method and to a medicament for use in the treatment of COVID-19 and related pathologies, the medicament comprising or interacting with one or more conserved regions of at least 4 consecutive amino acids with a 100% match present in both the SARS-CoV-2 proteome and the human proteome, wherein the one or more conserved regions are preferably selected by: a. identification of one or more conserved regions of at least 4 consecutive amino acids with a 100% match between the SARS-CoV-2 proteome and the human proteome; b. identification of at least one pathway class from a systematic database comprising a plurality of human physiological pathway classes, each class comprising a plurality of human proteins that are functionally related to the said physiological pathway, wherein the said at least one pathway class shares at least one pathology and/or complication of the COVID-19 infection as a result of dysfunction in the said pathway and comprises at least one human protein comprising one or more conserved regions of at least 4 consecutive amino acids that have a 100% match with the SARS-CoV-2 proteome; and c. selecting the said identified one or more conserved regions for the preparation of the medicament. Based on this approach peptides were selected for the treatment of COVID-19 and several pathologies and complications that can occur in the context of COVID-19, but also as a separate disease, pathology, or complication. The invention also relates to a v

COMPOSITIONS AND METHODS FOR DEBULKING VIRUS OR MICROORGANISM LOAD IN THE ORAL CAVITY

Absstract of: US2024277819A1

Compositions and methods for reducing viral load in the oral cavity, particularly Coronavirus such as SARS-CoV-2 and Influenza viral loads are disclosed. Also disclosed are compositions and methods for reducing bacterial or fungal loads in the oral cavity. The compositions comprise a trapping molecule having binding affinity for a protein, glucan, or other molecule on the surface of a virus or microorganism. A carrier appropriate for oral administration, in the form of a chewing gum, long-acting lozenge, or tablet, is further disclosed, to enable easy administration before or after exposure to the infective agent.

SUPPRESSION OF COVID-19 REPLICATION BY COVID-19 ENTRY INHIBITORS

Absstract of: US2024277730A1

The present invention relates to compounds, compositions, and methods, for treating viral infections. In particular, entry inhibitor compounds are disclosed for treatment of coronavirus infections, including SARS-COV-1 and SARS-COV-2 infections. The compounds bind to the interface of a SARS-COV-2 spike protein receptor binding domain (RBD) and a host cell ACE-2 receptor. The entry inhibitor compounds show antiviral activity, favorable kinetics, and temporally act at the entry of SARS-COV-2 infection. In embodiments, the compounds are used as medicaments for the inhibition of viral replication including SARS-COV-1 and/or SARS-COV-2 replication, for the treatment or prophylaxis of viral infections including SARS-COV-1 and SARS-COV-2 infections, and/or for the treatment or prophylaxis of an illness due to SARS-COV-1 and SARS-COV-2 infections.

A RAPID MULTIPLEX RPA BASED NANOPORE SEQUENCING METHOD FOR REAL-TIME DETECTION AND SEQUENCING OF MULTIPLE VIRAL PATHOGENS

Absstract of: US2024279751A1

Methods for the rapid and accurate detection and characterization of a viral nucleic acid in a sample are provided. The method is a method for multiplex isothermal amplification-based sequencing and real-time analysis of multiple viral genomes. It can simultaneously detect SARS-CoV-2 and co-infecting respiratory viruses, and monitor mutations for up to 96 samples in real time. The method, termed NIRVANA for Nanopore sequencing of Isothermal Rapid Viral Amplification for Near real-time Analysis, showed high sensitivity and specificity for SARS-CoV-2 in 70 clinical samples. It also simultaneously detected other viral pathogens (e.g. influenza A) in clinical and municipal wastewater samples. It provides a rapid field-deployable solution of COVID-19 and co-infection detection and surveillance of the evolution of pandemic strains.

ASSAYS FOR SARS-COV-2 BY LESION INDUCED DNA AMPLIFICATION (LIDA)

Absstract of: US2024279753A1

Assays for SARS-CoV-2 are described, together with lesion induced DNA amplification (LIDA)-based methods for amplifying RNA or DNA.

Diagnostic Primers, Kits and Methods for Viral Detection

Absstract of: US2024279750A1

Provided is a primer set for detecting the N gene of SARS-COV-2 using a reverse transcription loop-mediated isothermal amplification (RT-LAMP) method, comprising at least a first F3 primer comprising a nucleotide sequence at least 90% identical to SEQ ID NO: 1, at least a first B3 primer comprising a nucleotide sequence at least 90% identical to SEQ ID NO: 2, at least a first F2 primer comprising a nucleotide sequence at least 90% identical to SEQ ID NO: 3, at least a first B2 primer comprising a nucleotide sequence at least 90% identical to SEQ ID NO: 4, at least a first F1c primer comprising a nucleotide sequence at least 90% identical to SEQ ID NO: 5 or to SEQ ID NO: 8, at least a first B1c primer comprising a nucleotide sequence at least 90% identical to SEQ ID NO: 6. Also provided are kits and methods for using the described primers, and a primer set for similarly detecting the S gene of SARS-COV-2.

MULTIPLEXED ANTIGEN-BASED DETECTION OF SARS-COV-2 AND OTHER DISEASES USING NANOMECHANICAL SENSORS

Absstract of: US2024277252A1

Nanomechanical sensors comprising an antibody-functionalized microcantilever and methods of using the same are described herein.

SMALL MOLECULE COMPOUNDS

Absstract of: US2024279172A1

The SARS-CoV-2 is highly contagious and has caused coronavirus disease 2019 (COVID-19) outbreaks worldwide. Some embodiments of the present invention relate to a method of ameliorating or treating a subject suffering from a SARS-CoV-2 infection. The method includes administering to the subject an antiviral composition comprising a therapeutically effective amount of a GC molecule or a pharmaceutically acceptable salt thereof.

CORE AMINO ACID SEQUENCE GROUP CAPABLE OF TARGET RECOGNIZING ANTI-NOVEL CORONAVIRUS NEUTRALIZING ANTIBODIES N-IGY-PABS AND USE THEREOF

Absstract of: US2024279286A1

Specifically disclosed are a core amino acid sequence group capable of target recognizing anti-novel coronavirus neutralizing antibodies N-IgY-pAbs and a use thereof. The core amino acid sequence group capable of target recognizing anti-novel coronavirus neutralizing antibodies N-IgY-pAbs includes 15 types of the amino acid sequences positioned in an S-ECD region and 5 types of the amino acid sequences positioned in a non-structural protein (NSP) region, and can be applied to a detection of the novel coronavirus, a design of therapeutic targets and a design of vaccine targets.

PROTEIN-DERIVED PEPTIDE FOR IMPROVING IMMUNITY AGAINST 2019 NOVEL CORONAVIRUS (2019-nCoV) AND USE THEREOF

Absstract of: US2024279279A1

In some embodiments, the disclosure provides a hazelnut-derived peptide with an inhibitory activity against a 2019 novel coronavirus main protease (2019-nCoV M-pro), including an amino acid sequence of Trp-Trp-Asn-Leu-Asn (WWNLN). In other embodiments, the disclosure provides use of the hazelnut-derived peptide with an inhibitory activity against a 2019-nCoV M-pro in preparation of a drug, a health product, or a food supplementary for inhibiting a 2019-nCoV infection. In further embodiments, the derived peptide WWNLN in the disclosure has a high 2019-nCoV M-pro inhibitory activity, with an inhibition rate of 74.13%±1.93% and a half maximal inhibitory concentration (IC50) value of 6.695 μM. In some embodiments, the derived peptide may be used to prepare drugs, health products, or foods supplementary that inhibit 2019-nCoV infections, and may show desirable application prospects.

A FAST DIAGNOSTIC KIT FOR DETECTING COVID-19

Absstract of: WO2024170929A1

A diagnostic kit for detecting the CO VID- 19 is developed that the diagnostic kit comprises a positive control, a negative control, at least one reverse transcriptase (RT) enzyme, a a master mix; and a prop primer mix. The disclosed diagnostic kit is capable of detecting an amount of the virus loading in at least three genes simultaneously through an optimal selection of at least three target genes, at least three pairs of probes, and at least three pairs of specific primers for the target genes. This selection make the diagnostic kit detecting the target genes in less than 55 minutes and provide a suitable conditions to prevent progressing the Covid- 19 and serious issues in a patient.

A RESPIRATORY SUPPORT APPARATUS

Absstract of: US2024277966A1

Embodiments of a respiratory support apparatus are disclosed comprising features configured to minimize, reduce or contain aerosols carrying pathogens that can cause diseases such as COVID 19, SARS, MERS, Tuberculosis, or any other infectious diseases. Embodiments of a respiratory support apparatus are also provided configured to at least reduce the amount of oxygen required, during use of the apparatus, from an external oxygen supply such as an oxygen tank or hospital wall supply. Embodiments of such apparatus are provided with means to recirculate expiratory gases, and/or redirect leak flow. Embodiments of such apparatus are provided in which expiratory gases are sucked away from the patient. Embodiments of such apparatus are provided comprising a first flow generator for delivering inspiratory gases, and a second flow generator for removing expiratory gases.

ACE2-TARGETED COMPOSITIONS AND METHODS FOR TREATING COVID-19

Absstract of: AU2022367398A1

This invention provides a monoclonal antibody that (i) specifically binds to the extracellular portion of human angiotensin converting enzyme 2 (hACE2); (ii) specifically inhibits binding of SARS-CoV-2 to the extracellular portion of hACE2; and (iii) does not significantly inhibit the ability of hACE2 to cleave angiotensin II and/or a synthetic MCA-based peptide. This invention also provides related recombinant AAV vectors, recombinant AAV particles, compositions, prophylactic and therapeutic methods, and kits.

New medical use

Absstract of: GB2627263A

The compound sevuparin (a modified heparin) or a pharmaceutically acceptable salt thereof, for use in the treatment of endotoxemia. The treatment may be prophylactic. The endotoxemia may occur in conjunction with gram-negative or gram-positive bacteria, sepsis, septic shock, major surgical procedure(s) (e.g., thoracic (cardiac), abdominal, neurosurgical procedure), severe acute disease (e.g., pancreatitis, cholecystitis, intestinal arterial obstruction, portal vein thrombosis, aortic aneurysm rupture, aortic dissection), injury from major trauma, hepatic failure (non-cirrhotic or cirrhotic), hepatorenal syndrome, intestinal endotoxemia. The endotoxemia may be portal endotoxemia, or may be present in a subject having an autoimmune disease (e.g., inflammatory bowel disease (IBD), Crohn’s disease, ulcerative colitis), systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), or Covid-19. The use may be combination treatment with standard of care (SOC) therapy (e.g., low molecular weight heparin (LMWH)) for endotoxemia. Also claimed is the use of compound sevuparin or its pharmaceutically acceptable salt, for the manufacture of a medicament for the treatment of endotoxemia. Also claimed is a method of treatment of endotoxemia, comprising administering a therapeutically effective amount of sevuparin or its pharmaceutically acceptable salt, to a subject.

MODIFIED MULTABODY CONSTRUCTS, COMPOSITIONS, AND METHODS TARGETING SARS-COV-2

Absstract of: CA3235530A1

A self-assembled polypeptide complex comprises: (a) one or more fusion proteins comprising a nanocage monomer or subunit thereof linked to an Fc polypeptide, and (b) one or more fusion proteins comprising a nanocage monomer or subunit thereof linked to a SARS-CoV-2 binding moiety; wherein a plurality of the fusion proteins self-assemble to form a nanocage.

GENE CONSTRUCT FOR EXPRESSING MRNA

Absstract of: EP4417694A1

The present invention relates to a gene construct for expressing an mRNA, and a pharmaceutical composition, a vaccine composition, and a gene therapy composition, each comprising the gene construct. More specifically, the present invention relates to a gene construct including a coronavirus (SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2)-derived 5' untranslated region (UTR) and/or 3' untranslated region (UTR), and a pharmaceutical composition, a vaccine composition, and a gene therapy composition, each comprising the gene construct.

EXPRESSION OF SARS-COV PROTEINS, NUCLEIC ACID CONSTRUCTS, VIRUS LIKE PROTEINS (VLPS) AND METHODS RELEVANT THERETO

Absstract of: US2024269261A1

The present invention relates to expression of SARS-CoV like virus proteins S, M and E proteins; recombinant polynucleotides, polypeptides; constructs, virus-like particles (VLPs); immunogenic compositions or vaccines comprising Virus Like Particles (VLPs). Method of producing the VLPs/expressing the multi-subunit virus like proteins and method for co-expression of multi-subunit and virus like proteins (VLPs) are also provided. The present invention also provides strategies, methods, systems, kits and combinations for scalable expression, purification and enhanced production of the virus like proteins of SARS-CoV while maintaining their size range and composition. Such multi-subunit VLPs can be utilized to make immunogenic compositions or vaccines.

ANTIBODY MOLECULES BINDING TO SARS-COV-2

Absstract of: WO2024168061A2

Antibody molecules that specifically bind to a SARS-CoV-2 spike protein are disclosed. The antibody molecules can be used to treat, prevent, and/or diagnose disorders, such as COVID-19.

COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING LUNG DISEASE

Absstract of: US2024269242A1

Provided herein are compositions and methods for treating and preventing lung disease. In particular, provided herein are SP-A peptides and uses thereof in the treatment and prevention of lung disease (e.g., asthma or COPD). The compositions may comprise peptides having an amino acid sequence of Ac-WGKEQCVE(Nle)(Pego3)-Hdc (SEQ ID NO: 24) The peptide compositions may also be used to treat COVID-19.

METHODS RELATED TO AN ALTERNATIVE CONFORMATION OF THE SARS-COV-2 SPIKE PROTEIN

Absstract of: US2024274239A1

Described are methods related to a newly discovered alternative conformation of the SARS COV 2 Spike protein.

CRISPR-CAS13 SYSTEM FOR DETECTING SARS-COV-2, AND KIT THEREOF AND METHOD THEREFOR

Absstract of: WO2024164381A1

Provided are a CRISPR-Cas 13 system for detecting SARS-CoV-2, and a kit thereof and a method therefor. The CRISPR-Cas13a system comprises Cas13a protein and crRNA or a complex formed by the Cas13a protein and the crRNA. The crRNA comprises a first guide RNA and a second guide RNA, and the first guide RNA and the second guide RNA are respectively selected from at least one of sequences SEQ ID NOs.1-33. The system, the kit and the method have the advantages of a simple scheme and high sensitivity, and can be accurately used for detecting SARS-CoV-2.

MODIFIED PIV5 VACCINE VECTORS: METHODS OF MAKING AND USES

Absstract of: WO2024167866A2

A CVB viral expression vector comprising a PIV5 W3A viral genome that contains mutations at amino acid residue S157 or S156 in the P/V gene and a deletion of the small hydrophobic (SH) gene of the PIV5 W3A viral genome, wherein the amino acid substitution at amino acid residue S157 or S156 comprises a substitution of serine (S) to phenylalanine (F) or asparagine (N) and wherein the SH gene has a deletion of the SH open reading frame or a deletion of an entire SH gene transcript unit. The CVB viral expression vector wherein the vector expresses a heterologous polypeptide comprising a SARS-CoV-2 spike (S), and/or nucleocapsid (N) and/or membrane (M) proteins, RSV fusion protein (F) or other antigens.

SARS-CoV-2 DETECTION METHOD AND KIT THEREFOR

Absstract of: WO2024166923A1

Disclosed are a high-performance anti-SARS-CoV-2 antibody, and a testing reagent using the anti-SARS-CoV-2 antibody. This SARS-CoV-2 detection method involves detecting SARS-CoV-2 in a sample by immunoassay using a monoclonal antibody or an antigen-binding fragment thereof that specifically reacts with an RNA-binding domain of an amino acid sequence of the SARS-CoV-2 N protein. This SARS-CoV-2 detection kit includes a monoclonal antibody or an antigen-binding fragment thereof that specifically reacts with an RNA-binding domain of the SARS-CoV-2 N protein.

SARS-CoV-2 DETECTION METHOD AND KIT THEREFOR

Absstract of: WO2024166921A1

Disclosed are a high-performance anti-SARS-CoV-2 antibody, and a testing reagent using the anti-SARS-CoV-2 antibody. This SARS-CoV-2 detection method includes detecting SARS-CoV-2 in a sample by immunoassay using a monoclonal antibody or an antigen-binding fragment thereof that specifically reacts with 301aa-319aa, 301aa-320aa or 351aa-375aa of the amino acid sequence of the SARS-CoV-2 N protein. This SARS-CoV-2 detection kit includes a monoclonal antibody or an antigen-binding fragment thereof that specifically reacts reacts with 301aa-319aa, 301aa-320aa or 351aa-375aa of the amino acid sequence of the SARS-CoV-2 N protein.

ANTI-SARS-COV-2 MONOCLONAL ANTIBODY AND IMMUNOASSAY METHOD AND IMMUNOASSAY INSTRUMENT FOR SARS-COV-2 USING SAME

Absstract of: WO2024166920A1

Disclosed are: a monoclonal antibody with which SARS-COV-2 contained in a test specimen can be rapidly, simply and highly sensitively detected and measured; and an immunoassay method and an immunoassay instrument for SARS-COV-2 using the monoclonal antibody. This monoclonal antibody or an antigen-binding fragment thereof includes heavy chains CDR1-CDR3 having specific amino acid sequences and light chains CDR1-CDR3 having specific amino acid sequences. This immunoassay method for SARS-COV-2 involves performing an immunoassay of SARS-COV-2 using an antigen-antibody reaction between the monoclonal antibody or an antigen-binding fragment thereof and SARS-COV-2 in a sample.

SARS-CoV-2 DETECTION METHOD AND KIT THEREFOR

Absstract of: WO2024166922A1

Disclosed are a high-performance anti-SARS-CoV-2 antibody, and a testing reagent using the anti-SARS-CoV-2 antibody. This SARS-CoV-2 detection method involves detecting SARS-CoV-2 in a sample by immunoassay using a monoclonal antibody or an antigen-binding fragment thereof that specifically reacts with the SARS-Cov-2 N protein. This SARS-CoV-2 detection kit includes a monoclonal antibody or an antigen-binding fragment thereof that specifically reacts with the SARS-Cov-2 N protein.

NOVEL LOW-TEMPERATURE-ADAPTIVE ATTENUATED MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS

Absstract of: WO2024167071A1

The present invention relates to a novel low-temperature-adaptive attenuated Middle East respiratory syndrome coronavirus (MERS-CoV) and uses thereof, in which, by stepwise adapting a MERS-CoV to low temperatures, a novel low-temperature-adaptive attenuated MERS-CoV that enables effective prevention of MERS-CoV infection was developed, and can be useful as a vaccine and therapeutic agent able to prevent Middle East respiratory syndrome.

LIQUID PREPARATION CONTAINING NIRMATRELVIR AND RITONAVIR, AND PREPARATION METHOD THEREFOR AND USE THEREOF

Absstract of: WO2024165081A1

Provided are a liquid preparation containing nirmatrelvir and ritonavir, and a preparation method therefor and the use thereof. Nirmatrelvir, ritonavir and other excipients are combined to prepare the liquid preparation, which has a high absorption rate, a high bioavailability and an accurate administration dosage and can be accurately administered at a reasonable dosage according to different symptoms. The phenomena that an existing Paxlovid tablet is inconvenient to administer due to the large dosage, has a low dissolution and poor bioavailability, and that multiple tablets need to be taken are solved, the patient medication adherence is improved, and the drug toxicity is reduced. The preparation process of the liquid preparation containing nirmatrelvir and ritonavir is simple, and large equipment is not needed. The liquid preparation containing nirmatrelvir and ritonavir retains the drug properties of nirmatrelvir and ritonavir, and can be used for preparing drugs for SARS-CoV-2.

Methods for treating SARS CoV-2 infections

Absstract of: AU2024205205A1

Provided are methods for treating 2019-nCoV virus (SARS-CoV-2) infections by administering nucleosides and prodrugs thereof, of Formula I: w3 Ri2 wherein the l' position of the nucleoside sugar is substituted.

METHODS OF ANALYZING SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR 2 (STNFR2) AND USES THEREOF

Absstract of: AU2023213693A1

The present disclosure relates to methods of testing immunomodulatory activity of cells, including, for example, mesenchymal stem cells and uses of said cells that are determined as having immunomodulatory activity for treating COVID-19 related acute respiratory distress syndrome (ARDS). Disclosed herein are in vitro methods of evaluating mesenchymal stem cells for their effective immunomodulatory effects in vivo.

ANTI-SARS-COV-2 ANTIBODIES DERIVED FROM CR3022

Absstract of: US2024270825A1

This disclosure provides antibodies and that can be administered to an individual that is infected with a virus. Antibodies herein can be capable of treating or curing the virus, and which may provide protection against the virus for up to several weeks. Antibodies herein can be used to diagnose a SARS-CoV-2 infection.

ANTIBODIES THAT BIND SARS-COV-2 SPIKE PROTEIN

Absstract of: US2024270826A1

Described herein are antibodies that specifically recognize the SARS-CoV-2 spike (S) polypeptide, compositions comprising said antibodies, uses thereof, and methods employing said antibodies. Each antibody specifically recognizes the S1-RBD domain, S1-NTD domain, or S2 subunit of the SARS-CoV-2 spike polypeptide. Some antibodies are cross-reactive with variants of SARS-CoV-2 and other coronavirus spike polypeptides, such as SARS-CoV S, pangolin CoV S, bat SARS-like CoV S, and civet SARS-CoV S.

HUMAN NEUTRALIZING ANTIBODIES AGAINST SARS-COV-2 SPIKE S2 DOMAIN AND USES THEREOF

Absstract of: US2024270828A1

The disclosure is based, at least in part, on certain human monoclonal antibodies, or antigen binding fragments thereof, having unexpected broad neutralizing activities against SARS-CoV-2. The disclosed antibodies and/or antigen-binding fragments thereof are therapeutic agents for the treatment of SARS-CoV-2 infections and are suitable for use in therapeutic methods to protect individuals from SARS-CoV-2 infections.

CORONAVIRUS NEUTRALIZING COMPOSITIONS AND ASSOCIATED METHODS

Absstract of: US2024270797A1

Provided are fusion proteins and modified proteins comprising a neutralizing polypeptide and an antibody (e.g., a non-neutralizing antibody) that specifically binds to an epitope in a conserved region of one or more coronavirus spike proteins. The fusion proteins and modified proteins are able to specifically bind to and neutralize a broad spectrum of coronaviruses, including SARS-CoV-2 and all known SARS-COV-2 variants of concern (e.g., the Delta and Omicron variants). Also provided are various compositions of such proteins, methods of their use, nucleic acids encoding such proteins or domains thereof, constructs, expression cassettes, and vectors containing such nucleic acids, and host cells capable of expressing these proteins or domains thereof. Additionally provided are prophylactic and therapeutic methods employing the fusion proteins and/or modified proteins of the disclosure.

SESQUITERPENOID DERIVATIVE AND USE THEREOF IN PREPARING BROAD-SPECTRUM ANTIVIRAL DRUG

Absstract of: US2024270754A1

A sesquiterpenoid derivative and use thereof in preparing a broad-spectrum antiviral drug provided. The sesquiterpenoid derivative can stimulate heterogeneous nuclear ribonucleoprotein A2/B1, activate the cell signal pathway of TANK-binding kinase 1-interferon regulatory factor 3, and increase the expression and secretion of endogenous type I interferon. As a result, it can inhibiting various viruses and can be used as a broad-spectrum antiviral drug for preventing or treating various viral infectious diseases and symptoms, including Covid-19, vesicular stomatitis virus VSV-G, AIDS virus, hepatitis C virus, Japanese encephalitis virus, influenza virus, poliovirus, Coxsackie virus, dengue virus, rotavirus, tobacco mosaic virus, measles virus, mumps virus, Ebola virus, Marburg virus, herpes virus and adenovirus. Sesquiterpenoid derivatives can be made as a raw material into oral dosage form such as tablet, capsule and dripping pill, or clinically acceptable pharmaceutical preparation such as inhalant and injection.

Airborne monitor to detect SARS-CoV-2 wild-type and mutations in airborne samples using Nucleic Acid Amplification Techniques (NAT)

Absstract of: US2024269671A1

The disclosure provides example devices and methods for virus and bacterium detection and identification. The example device includes (a) a housing having an air inlet and an air outlet, (b) a substrate disposed within the housing, where the at least one substrate has a through-slot, where the substrate has a plurality of wells, (c) an air-handling and precipitation chamber, a reagent and reaction chamber, and a detection chamber arranged in series and each coupled to the top surface of the substrate, (d) a first actuator coupled to the substrate and configured to rotate the substrate, (e) a second actuator coupled to and configured to rotate the air-handling and precipitation chamber, the reagent and reaction chamber, and the detection chamber, and (f) at least one processor electrically coupled to the air-handling and precipitation chamber, the reagent and reaction chamber, the detection chamber, the first actuator, and the second actuator.

FUSION PROTEINS COMPRISING SARS-COV-2 RECEPTOR BINDING DOMAIN

Absstract of: US2024270795A1

A fusion protein includes the SARS-COV-2 receptor binding domain (RBD) of the SARS-COV-2 spike protein or a fragment, and a N-terminal signal peptide, and at least one of the following: a polyhistidine tag, linker, an oligomerization tag, a region in spike protein outside RBD, a horseradish peroxidase binding domain or a protease cleavage site.

TEMPERATURE-CONTROLLABLE, SELF-REPLICATING RNA VACCINES FOR VIRAL DISEASES

Absstract of: US2024269268A1

The present disclosure relates to mRNA, self-replicating RNA, and temperature-sensitive, self-replicating RNA encoding a coronavirus nucleocapsid protein or an influenza virus nucleocapsid protein in operable combination with a mammalian signal peptide. The present disclosure relates to mRNA, self-replicating RNA, and temperature-sensitive, self-replicating RNA encoding other viral nucleocapsid protein(s) in operable combination with a mammalian signal peptide. The RNA constructs are suitable for active immunization against a virus in a mammalian subject, such as a human subject.

BROAD-SPECTRUM MULTI-ANTIGEN PAN-CORONAVIRUS VACCINE

Absstract of: US2024269266A1

Waning immunity induced by first-generation Spike-alone-based COVID-19 has failed to prevent immune escape by many variants of concern (VOCs) that emerged from 2020 to 2024, resulting in a prolonged COVID-19 pandemic. Thus, a next-generation Coronavirus (CoV) vaccine incorporating highly conserved non-Spike SARS-CoV-2 antigens is described herein. Conserved non-Spike T cell antigens in combination with a Spike antigen encapsulated in lipid nanoparticles: (i) Induced high frequencies of lung-resident antigen-specific CXCR5+CD4+ T follicular helper cells, GzmB+CD4+ and GzmB+CD8+ cytotoxic T cells, and CD69+IFN-γ+TNFα+CD4+ and CD69+IFN-γ+TNFα+CD8+ effector T cells; and (ii) Reduced viral load and COVID-19-like symptoms caused by various VOCs. The combined antigen/LNP-based pan-CoV vaccine could be rapidly adapted for clinical use to confer broader cross-protective immunity against emerging highly mutated and pathogenic VOCs.

HUMAN CORONAVIRUS 229E DERIVED PEPTIDES

Absstract of: US2024269264A1

The invention relates to common cold coronavirus peptides derived from HcoV-229E, and related polynucleotides, complexes pharmaceutical compositions, methods of treatment, and medical uses.

METHODS, KITS, AND APPROACHES FOR VIRAL VACCINES

Absstract of: US2024269262A1

The invention provides methods of making vaccines against viruses, including against SARS-Cov-2. Such methods entail identifying areas of a viral genome that are highly conserved and making vaccines that target the highly conserved areas. The invention provides a polypeptide vaccine comprising a SARS-Cov-2 polypeptide or an immunogenic fragment thereof and a pharmaceutically acceptable excipient. The invention provides a polynucleotide vaccine comprising a polynucleotide encoding a SARS-Cov-2 polypeptide or immunogenic fragment thereof linked to a heterologous promoter and a pharmaceutically acceptable excipient. The invention provides methods for effecting prophylaxis of or treating SARS-Cov-2 infection comprising a step of administering a polypeptide vaccine and/or a polynucleotide vaccine to a subject in need thereof.

COVID-19 VACCINES WITH TOCOPHEROL-CONTAINING SQUALENE EMULSION ADJUVANTS

Absstract of: US2024269270A1

Provided are novel vaccines for prophylactic treatment of SARS-COV-2 infections and COVID-19 and methods of making the vaccines, wherein the vaccines contain an oil-in-water emulsion comprising tocopherol and squalene.

LIDOCAINE OR ARTICAINE FOR TREATING COVID-19, AUTOIMMUNE DISEASE OR CYTOKINE STORM RESPONSE

Absstract of: US2024269109A1

A composition including lidocaine or a salt thereof, or articaine or a salt thereof, is disclosed for use in the treatment of COVID-19 or an autoimmune disease or a condition in which an immune response caused by a disease or infection causes a cytokine storm. A pharmaceutical formulation including lidocaine, or a salt thereof, or articaine, or a salt thereof is disclosed. The pharmaceutical formulation is formulated to facilitate uptake by a lymphatic system with one or more suitable excipients.

METHOD FOR OPTIMIZING VIRUS MEMBRANE FUSION INHIBITOR, BROAD-SPECTRUM ANTI-CORONAVIRUS LIPOPEPTIDE AND USE THEREOF

Absstract of: EP4414377A1

The present disclosure relates to a method for optimizing a virus membrane fusion inhibitor, a broad-spectrum anti-coronavirus lipopeptide and use thereof. The present disclosure provides compounds or pharmaceutically acceptable salts thereof or derivatives thereof, wherein the compounds are shown in formula (I) or formula (II), X₁ is an amino-terminal protecting group; X₂ is a polypeptide with an amino acid sequence of (EAAAK)n or A(EAAAK)nA; X₃ is lysine or cysteine or 2,3-diaminopropionic acid or ornithine or 2,4-diaminobutyric acid or 2,7-diaminoheptonic acid; X₄ is a lipophilic compound group modified on X₃ or X₄ is a lipophilic compound group modified on K in X₂; X₅ is a carboxyl-terminal protecting group. The compounds of the present disclosure have a stable property, are highly efficient and broad-spectrum novel coronavirus membrane fusion inhibitors, and used in preparation of pharmaceutical compositions for preventing and treating a disease caused by a coronavirus. The pharmaceutical compositions are used for preventing and treating the diseases caused by the coronavirus.

ANTI-SARS-COV-2 ANTIBODIES AND USES THEREOF I

Absstract of: AU2022361501A1

The present disclosure relates to proteins which bind to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and uses thereof.

ANTI-SARS-COV-2 ANTIBODIES AND USES THEREOF II

Absstract of: AU2022358743A1

The present disclosure relates to anti-SARS-COV-2 antibodies and uses thereof in detecting intact multimeric and/or intact trimeric severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein in a sample.

ANTIBODIES TO CORONAVIRUS SARS-COV-2

Absstract of: WO2023070051A1

Described herein are antibodies or variants thereof that specifically bind to coronavirus antigens, such as SARS-CoV-2 antigens. The antibodies can be neutralizing antibodies. Also provided are methods of using the antibodies, including methods of treating a subject infected with SARS-CoV-2, and methods of diagnosing a subject infected with SARS-CoV-2.

PEDIATRIC SARS-COV-2 ANTIBODIES AND USES THEREOF

Absstract of: WO2024163949A2

The present disclosure relates to antibodies and uses thereof for treating, preventing, and detecting coronavirus infection.

RESPIRATORY BIOMARKER PANEL

Absstract of: WO2024163366A2

The present disclosure provides a set of primers and optional probes for identifying the presence of α-coronavirus, β-coronavirus, SARS-CoV-2, adenovirus, Chlamydia pneumoniae, Influenza A, Influenza B, metapneumovirus, rhinovirus/enterovirus, mycoplasma, Bordetella spp., parainfluenza, and respiratory syncytial virus (RSV), which can be included with (e.g., in at kit) or in a cartridge for automated detection of these pathogens by nucleic acid amplification. This disclosure also provides related detection methods, as well as cartridges, systems, and kits useful in such methods.

POLYCLONAL ANTIBODIES TO TREAT SARS-COV-2

Absstract of: WO2024163734A1

A composition, method of treating COVID-19, and use of the composition for administration to treat COVID-19 are provided. The composition includes polyclonal antibodies derived from human milk. The human milk is pooled and selected from human milk with polyclonal antibodies that includes an intact antibody that recognize SARS-CoV-2 viral particles

APTAMER BASED DETECTION OF SARS-COV-2 INFECTION

Absstract of: WO2024161418A1

The present invention relates to development of novel ssDNA aptamers comprising the oligonucleotide sequence that detect receptor-binding domain (RBD) of Severe Acute Respiratory Syndrome Corona virus (SARS-nCoV-2) infection. The ssDNA aptamers of the present invention may be used in lateral flow assays, electrochemical sensors and calorimetric sensors using gold nanoparticles. The present invention also relates to an analytical composition comprising said ssDNA aptamers. Further, the present invention also relates to a diagnostic kit for detecting RBD of SARS-nCoV-2.

CAMELID-DERIVED NANOBODY TARGETING SHARED EPITOPE OF SARS-COV-2 RBD AND RECEPTOR ACE2 THEREOF

Absstract of: WO2024159694A1

A camelid-derived nanobody targeting a shared epitope of SARS-CoV-2 RBD and receptor ACE2 thereof. The nanobody or an antigen binding fragment thereof simultaneously binds to key sites F486, Q493 and S494 of SARS-CoV-2 RBD. The nanobody VHH5-05 obtained by means of screening and purification not only exhibits a strong binding ability to a phage displaying the wild-type SARS-CoV-2 RBD, but also exhibits a certain binding ability to a phage displaying the Beta mutant strain RBD and the Delta mutant strain RBD.

CRISPR-Cas13 System, Kit and Method for Detecting SARS-CoV-2

Absstract of: US2024263256A1

Provided herein is a CRISPR-Cas13 system, a kit and a method for detecting SARS-COV-2. The CRISPR-Cas13a system includes a Cas13a protein and crRNA, or a complex formed by Cas13a protein and crRNA. The crRNA includes a first guide RNA and a second guide RNA, the first guide RNA and the second guide RNA having at least one sequence selected from SEQ ID NOs: 1 to 33, respectively.

BOOSTING SARS-COV-2 IMMUNITY WITH A LENTIVIRAL-BASED NASAL VACCINE

Absstract of: AU2023207825A1

The invention relates to the field of immunity against coronaviruses. In this respect, the invention provides a lentiviral-based immunogenic agent that is suitable for use in boost or target immunization treatment in a subject, in particular a human subject, who had previously developed an immunity against Severe Acute Respiratory Syndrome coronavirus 2 (SARS- CoV-2) based on: (i) vaccination with the first generation of vaccines against SARS-CoV-2 infection or disease such as a protein, an mRNA, an adenovirus, an inactivated virus or a protein subunit vaccine composition against SARS-CoV-2 infection or disease, in particular a protein- or an mRNA-based vaccine, or (ii) SARS-CoV-2-induced or correlated disease. The invention accordingly concerns a lentiviral-based immunogenic agent that in particular may help overcome the deficiencies of available vaccines against SARS-CoV-2, especially may be efficient in overcoming the waning immune response or insufficient cellular memory response observed after immunization with available first generation of vaccines such as a protein, an mRNA, an adenovirus, an inactivated virus or a protein subunit vaccine, in particular protein or mRNA vaccine, by triggering a mucosal humoral and cellular immune response against coronaviruses, including a long-lasting immune response.

METHODS AND COMPOSITIONS FOR TREATING INFLAMMATION INJURY IN THE LUNGS

Absstract of: AU2023209914A1

Compositions and methods related to the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) including viral pneumonia (such as COVID-19 pneumonia) wherein the subject has a PaO

PSEUDOTYPED LENTIVIRAL VECTORS

Absstract of: AU2022422579A1

The present invention relates to pseudotyped lentiviral vectors, particularly to pseudotyped with a modified severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, as well as related constructs, methods and therapeutic indications.

VACCINE COMPOSITIONS AND THEIR USE

Absstract of: AU2022418989A1

The invention relates to immunogenic compositions and their use as a vaccine for the prevention of coronavirus disease in a human subject. More specifically, the invention relates to methods of use of an immunogenic composition in the prevention of coronavirus disease in a human subject in need thereof, said immunogenic composition comprising: a fusion protein comprising (i) a SARS-Cov2 nucleocapsid N antigen and, (ii) a carrier protein comprising a self-assembling polypeptide derived from C4bp oligomerization domain and a positively charged tail.

TLR7 AGONIST CONJUGATED PEPTIDE-BASED NOVEL CORONAVIRUS NANOEMULSION VACCINE AND PREPARATION THEREOF

Absstract of: US2024261391A1

The present invention relates to a novel coronavirus vaccine using a TLR7 agonist conjugated peptide as an antigen and an emulsion as an adjuvant. An antigen polypeptide of the conjugated peptide is a polypeptide derived from an S protein of SARS-COV-2, and the adjuvant is an oil-in-water nanoemulsion containing squalene. The conjugated peptide nanoemulsion vaccine preparation of the present invention is thermally stable, and can induce a high level of protective humoral immune response in a cynomolgus monkey, and the neutralizing antibody titer of antiserum after immunization of cynomolgus monkey is high, such that invasion of wild-type strain and mutant novel coronavirus can be blocked. The vaccine of the present invention has a nearly complete protection effect on the upper and lower respiratory tracts of the cynomolgus monkey in a cynomolgus monkey SARS-COV-2 challenge test. The nanoemulsion vaccine of the present invention is fast and convenient to prepare, and can realize large-scale production in a short term for coping with the novel coronavirus outbreak.

NITRIC OXIDE DONORS, COMPOSITIONS, AND METHODS OF USE

Absstract of: US2024261243A1

Disclosed are compositions comprising NO donors formulated for effectively treating disease states, such as microbial infections, including Covid-19 infections. Mucoadhesive agents, chelating agents, and gallium enable highly efficacious formulations for treating infections, particularly when the nature of the pathogenic species is unknown.

SARS-COV-2 RNA VACCINE COMPOSITIONS AND METHODS OF USE

Absstract of: US2024261393A1

The disclosure provides compositions, methods of treatment, and methods of making and using compositions to deliver a nucleic acid to a subject. Methods of using the compositions as a COVID-19 vaccine for the treatment of a coronavirus infection are also provided.

COMPOSITIONS AND METHODS FOR INDUCING IMMUNE RESPONSES AGAINST CLASS I FUSION PROTEIN VIRUSES

Absstract of: US2024261394A1

Provided are modified bacteria and derivatives thereof that express nucleotide sequence encoding an antigen of a viral family selected from the group comprising Retroviridae (e.g., HIV, including a HIV Fusion Peptide antigen), Orthomyxoviridae, Paramyxoviridae, Arenaviridae, 5 Filoviridae, and/or Coronaviridae (e.g., an SARS-CoV, SARS-CoV-2 Fusion Peptide, and/or PEDV). In some embodiments, the bacterium has a reduced genome and induces an enhanced immune response against the viral antigen of interest when administered to a subject. In some embodiments, the viral (e.g., SARS-CoV, 10 SARS-CoV-2, PEDV, and/or HIV) antigen is expressed on a surface of a bacterium. Also provided are method for producing antibodies against viral antigens, vaccine compositions, methods for vaccinating subjects, methods for treating viral infections in subjects, and expression vectors for expressing viral antigens including but not limited to coronavirus (e.g., SARS-CoV, SARS-CoV-2, and/or PEDV) antigens and/or HIV antigens on the surface of reduced 15 genome bacteria.

INHIBITORS OF SARS-COV-2 VIRAL REPLICATION AND USES THEREOF

Absstract of: US2024261307A1

This invention is in the field of medicinal pharmacology. In particular, the present invention relates to pharmaceutical agents which function as inhibitors of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral replication and/or SARS-CoV-2 related viral 3CL protease (Mpro) activity, which function as therapeutics for the treatment of conditions caused by the SARS-CoV-2 virus (e.g., COVID-19), and which function as therapeutics for the treatment conditions related to SARS-CoV-2 related Mpro activity.

HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19

Absstract of: US2024261316A1

The present invention is the use of purine nucleotide phosphoramidates or pharmaceutically acceptable salts thereof administered in an effective amount for the treatment or prevention of COVID-19, an infection caused by the SARS CoV-2 virus in a host, for example a human, in need thereof.

A DEVICE FOR DETECTING HEALTH DISORDERS FROM BIOLOGICAL SAMPLES AND A DETECTION PROCESS

Absstract of: US2024264146A1

The present invention relates to instruments and processes for detecting compounds in gas samples. In particular, for detecting health disorders from biological samples, more preferably for detecting diseases from breath samples of a mammal. It is included among the methods and instruments for the diagnosis of COVID-19.

DEVELOPMENT AND VALIDATION OF A 2-GENE HOST-VIRAL TRANSCRIPTOMIC CLASSIFIER FOR ENHANCED COVID-19 DIAGNOSIS

Absstract of: US2024263254A1

Provided herein are lists of combined host-viral gene markers that can be used for identifying COVID-19 in a subject and/or determining severity of disease. The host-viral diagnostic methods, compositions and systems disclosed herein are used to classify human subjects pre-diagnosis, with or without symptoms of COVID-19, based on the expression levels of the identified gene markers.

POLYPEPTIDE FRAGMENTS, IMMUNOGENIC COMPOSITION AGAINST SARS-CoV-2, AND IMPLEMENTATIONS THEREOF

Absstract of: US2024262869A1

The present disclosure discloses the polypeptide fragment having an amino acid sequence with at least 95% identity to the amino acid sequence selected from the group consisting of SEQ ID NO: 2, SEQ ID NO: 4, and SEQ ID NO: 6. The present disclosure also discloses nucleic acid fragment encoding the polypeptide fragment as described herein. Moreover, the present disclosure also discloses recombinant construct, recombinant vector and recombinant host cells. Also disclosed herein is an immunogenic composition comprising the polypeptide fragment as described herein, and a method for preparing the said immunogenic composition. The immunogenic composition is in form of vaccine. The polypeptide fragment and/or immunogenic composition is capable of eliciting protection against severe acute respiratory syndrome coronavirus 2. A kit comprising the polypeptide, or the immunogenic composition as described herein is also disclosed.

NOVEL UNIVERSAL ANTI-RNA VIRUS AGENTS

Absstract of: US2024262857A1

Deuterated and/or methylated N4-hydroxycytidine (NHC) analogs, with deuteration at one or both of the 2′- and 3′-positions on the ribo-sugar moiety and/or methylation of the 3′-positions on the ribo-sugar moiety, pharmaceutical compositions comprising one or more of these compounds, and, optionally, at least one additional therapeutic agent, and methods of treating or preventing infections caused by RNA viruses, curing an infection by an RNA virus, or reducing the biological activity of an RNA virus, are disclosed. Representative RNA viruses include, but are not limited to, Coronaviridae, such as MERSr-CoV, SARS-CoV-1, SARSCoV-2, HCoV-OC43, HCoV-229E, HCoV-NL63, and HCoV-HKU1, Picornaviridae, Hepeviridae, Noroviruses, Zika, Dengue, Mayaro, Influenza A and B, Parainfluenza, HCV, Rinovirus, tick-borne viruses, Ebola, Lassa, RSV, adenoviruses, enteroviruses, metapneumoviruses, Eastern, Western, and Venezuelan Equine Encephalitis (EEE, WEE and VEE, respectively), and Chikungunya fever (CHIK).

BINDING POLYPEPTIDES AGAINST SARS COV-2 AND USES THEREOF

Absstract of: US2024262893A1

Provided herein are binding polypeptides, such as binding peptides and antibodies, against a SARS CoV-2. The binding polypeptides relate to or are based on bovine antibodies, particularly those containing an ultralong CDR3. Also provided herein are methods of treating a virus infection, such as a coronavirus infection, by delivering to a subject in need a provided binding polypeptide.

METHOD FOR PREDICTING DEVELOPMENT OF SEVERE SYMPTOM OF COVID-19 USING EXOSOMAL PROTEIN MARKER IN BLOOD

Absstract of: US2024263234A1

The present invention provides a method for predicting the development of a severe symptom in a COVID-19 patient using a level of RNA of COPB2, KRAS, PRKCB, RHOC, CD147, CAPN2, ECM1, FGG, MFAP4, ADI1, AK1, MGAT1, CLDN3, CRP, UQCRC2, FGA, FGB, FGL1, GPX1, GSK3B, LBP, PDGFC, RAB13, RAP1B, SLC6A4, UBA7, or the like contained in the blood of a patient.

NEUTRALIZING ANTIBODIES AGAINST SARS-COV-2

Absstract of: US2024262892A1

Provided are novel neutralizing antibodies against spike protein of SARS-COV-2, and the antigen binding fragments thereof. Pharmaceutical composition and kits comprising the same, and the uses thereof are also provided.

Optimized RNAi Agents for Inhibiting Expression of Coronavirus (CoV) Viral Genomes, Compositions Thereof, and Methods of Use

Absstract of: WO2024163750A2

Described are optimized RNAi agents, compositions that include RNAi agents, and methods for inhibition of coronavirus (CoV) viral genome. The optimized CoV RNAi agents and RNAi agent conjugates disclosed herein inhibit the expression of a SARS-CoV-2 viral genome, and the targeted portions of the genome are conserved across a variety of known coronaviruses. Pharmaceutical compositions that include one or more optimized CoV RNAi agents, optionally with one or more additional therapeutics, are also described. Delivery of the described CoV RNAi agents to pulmonary cells, in vivo, provides for inhibition of CoV viral genome expression, including SARS-CoV-2, which can provide a therapeutic benefit to subjects, including human subjects, for the treatment of various diseases including COVID-19.

COVID-19 A Machine Learning Model Learning Method Machine Learning-based COVID-19 Symptom Detection Method and Computer-readable Recording Medium on Which A Program Is Recorded

Absstract of: KR20240120370A

본 발명은 기계학습 모델 학습 방법, 기계학습 기반 COVID-19 전조증상 감지 방법 및 이를 수행하는 프로그램이 기록된 컴퓨터 판독이 가능한 기록매체에 관한 것으로, 보다 구체적으로, 적어도 하나의 프로세서에 의하여, 다수의 COVID-19 감염자가 각각 착용하고 있는 웨어러블 디바이스에 기록된 데이터가 학습 데이터로 획득되는 학습 데이터 획득단계, 상기 적어도 하나의 프로세서에 의하여, 상기 학습 데이터를 필터링한 후 이동평균(Moving Average; MA)이 이용되어 데이터 추세가 분석되는 학습 데이터 전처리 단계 및 상기 적어도 하나의 프로세서에 의하여, 전처리된 학습 데이터가 이용되어 지지 벡터 기반의 이상 탐지 기법으로 학습되고, COVID-19 감염증상여부를 출력하는 기계학습 모델이 생성되는 모델 학습 단계를 포함하는 기계학습 모델 학습 방법, 기계학습 기반 COVID-19 전조증상 감지 방법 및 이를 수행하는 프로그램이 기록된 컴퓨터 판독이 가능한 기록매체에 관한 것이다.

PROCYANIDINS FOR THE TREATMENT OF ENDOTHELIAL DYSFUNCTION TRIGGERED BY COVID-19

Absstract of: ZA202213765B

The invention relates to a natural composition for medical purposes and more specifically to a composition comprising procyanidins, for use in the prevention or treatment of endothelial inflammation and/or endothelial systemic dysfunction triggered by Corona virus disease 2019 (COVID-19) including symptomatic post-COVID-19 subjects recovering from COVID-19.

POLYMERS OBTAINED BY THE REACTION OF A PHENOLIC COMPOUND AND A CARBONYL COMPOUND AS ANTI-SARS-COV-2 AGENTS

Absstract of: WO2023052517A1

The present invention relates to a condensation product, obtained or obtainable by the reaction of phenol, formaldehyde, sulfuric acid and urea, or a pharmaceutical composition comprising the same for use in a method for the prevention or treatment of Coronavirus disease 2019 (COVID-19) and/or for the prevention or treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, to a pharmaceutical set comprising such a pharmaceutical composition for the same use and to such a pharmaceutical composition or pharmaceutical set.

PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING VIRAL INFECTIOUS DISEASES, CONTAINING EFAVIRENZ AND FLUOXETINE AS ACTIVE INGREDIENTS

Absstract of: EP4410293A1

The present invention relates to a pharmaceutical composition for preventing or treating viral infectious diseases, containing efavirenz and fluoxetine as active ingredients. It has been identified that when a complex, mixture or combination of efavirenz and fluoxetine is administered or a complex, mixture or combination of efavirenz and fluoxetine, to which a biguanide-based compound metformin is added, is administered, antiviral efficacy against various zoonotic viruses including SARS-CoV-2 is remarkably higher than when each is administered alone, and thus efavirenz and fluoxetine, in addition to the biguanide-based compound, can be effectively used as active ingredients of a composition for preventing or treating viral infectious diseases.

ANTIBODY SPECIFIC TO SPIKE PROTEIN OF SARS-COV-2 AND USES THEREOF

Absstract of: US2024228591A1

The present disclosure relates to an antibody or antigen-binding fragment thereof that specifically binds to a spike protein of SARS-COV-2. The present disclosure also relates to a pharmaceutical composition, a method for treating and/or preventing diseases and/or disorders caused by a coronavirus in a subject in need thereof, and a method for detecting a coronavirus in a sample.

RECOMBINANT NEWCASTLE DISEASE VIRUS EXPRESSING SPIKE PROTEIN OF SARS-COV-2 DELTA VARIANT AND USES THEREOF

Absstract of: WO2023056351A2

Described herein are recombinant Newcastle disease viruses ("NDVs") comprising a packaged genome, wherein the packaged genome comprises a transgene comprising a nucleotide sequence encoding a protein comprising a SARS-CoV-2 delta variant spike protein or portion thereof. Also described herein are recombinant NDVs comprising a packaged genome, wherein the packaged genome comprises a transgene encoding a chimeric F protein, wherein the chimeric F protein comprises a SARS-CoV-2 delta variant spike protein ectodomain and NOV F protein transmembrane and cytoplasmic domains. The recombinant NDVs and compositions thereof are useful for the immunizing against SARS- CoV-2 delta variant as well as the prevention of COVID-19.

COMPOSITIONS, KITS, AND METHODS FOR DUPLEX IMMUNOASSAY FOR ANTI-SARS-COV-2 ANTIBODIES

Absstract of: CN118043347A

Kits containing a multiplex chemiluminescent detection system and microfluidic devices and methods for detecting the presence and/or concentration of anti-SARS-CoV-2 antibodies in a sample are disclosed. Kits, microfluidic devices, and methods utilize singlet oxygen activatable chemiluminescent compounds in combination with two or more fluorescent molecules that emit light at different wavelengths. In certain non-limiting embodiments, the kits, microfluidic devices, and methods can differentiate an anti-SARS-CoV-2 antibody generated in response to vaccination from an anti-SARS-CoV-2 antibody generated in response to infection.

RECOMBINANT FUSION PROTEIN DERIVED FROM HR REGION OF S2 PROTEIN OF SARS-COV-2 AND APPLICATION OF RECOMBINANT FUSION PROTEIN

Absstract of: EP4410843A1

Disclosed are a recombinant fusion protein derived from an HR region of an S2 protein of SARS-CoV-2 and an application of the recombinant fusion protein. The SARS-CoV-2 recombinant fusion protein is a recombinant fusion protein obtained by linking two membrane fusion-related conserved amino acid sequences HR1 and HR2 of the SARS-CoV-2 membrane protein S2 protein by means of a linking peptide. The recombinant fusion protein can be induced and expressed in Escherichia coli, has high expression quantity, and is easy to purify. The SARS-CoV-2 recombinant fusion protein provided by the present invention can form and maintain a stable dimer structure, simulates the conformation of a SARS-CoV-2 membrane fusion intermediate state, can be used as a detection raw material for detecting a SARS-CoV-2 membrane fusion process, has good anti-SARS-CoV-2 activity and good immunogenicity, and has a wide application prospect in the fields of development of drugs for preventing or treating SARS-CoV-2 proteins and development of SARS-CoV-2 vaccines and anti-SARS-CoV-2 antibodies.

2 SARS-CoV-2 specific aptamer and use thereof

Absstract of: KR20240118210A

본 발명은 사스 코로나 바이러스 2(SARS coronaviru 2; SARS-CoV-2) 특이적 압타머 및 이의 용도에 관한 것이다. 보다 구체적으로 본 발명에서 제공하는 압타머는 사스 코로나 바이러스 2 스파이크 단백질, 특히 사스 코로나 바이러스 2 스파이크 단백질의 서브유닛 1에 높은 결합력으로 특이적 결합하므로 이를 이용하여 검출용 조성물, 키트 등에 유용하게 이용할 수 있다.

SULFONE-1H-PYRROLE-2-CARBOXAMIDE INHIBITORS OF SARS-COV-2 NSP14 METHYLTRANSFERASE AND DERIVATIVES THEREOF

Absstract of: WO2024158875A1

Methods and compositions for treating SARS-CoV-2 and COVID-19 are disclosed. Sulfone-1H-pyrrole-2-carboxamides of the following formula inhibit the SARS-CoV-2 PLpro/NSP3 protein and are therefore useful for treating SARS-CoV-2 and COVID-19.

COMPOSITIONS AND METHODS USING TETRAHYDROCANNABINOL AND COMPOSITIONS INCLUDING SAME FOR TREATING INDICATIONS INVOLVING INFLAMMATION

Absstract of: WO2024159198A2

Compositions and methods for treating any one of the disclosed indications involving inflammation in a subject in need thereof, which includes administering to the subject a therapeutically effective amount of a composition including a tetrahydrocannabinol (THC) constituent. The composition is beneficial in reducing inflammation and/or inhibiting the production of pro-inflammatory cytokines and/or converting inflammatory M1 phenotype macrophages into anti-inflammatory M2 phenotype macrophages. It is useful in treating indications such as COVID-19, PASC/long COVID, effects related to ROSC, exposure to chemical or biological weapons, chemotherapy side effects, graft versus host disease, kidney damage from inflammation, chronic obstructive pulmonary disease, aging, and ARDS resulting from COVID-19, mechanical ventilation, shock, sepsis. In further embodiments, the composition may further include fluvoxamine, melatonin, or other disclosed constituents.

SARS-COV-2 VACCINE CONSTRUCTS

Absstract of: WO2024158722A1

The present disclosure describes, inter alia, fusion polypeptides comprising a SARS-CoV-2 Spike polypeptide fragment comprising at least a portion of the N-terminal domain, domains CD1, RBM, and CD2, and at least a portion of CTD1, wherein the N- or C-terminus of the Spike polypeptide fragment is fused to a heterologous N- or C-terminal tag comprising at least two, at least three, or at least four amino acids, as well as polynucleotides and vectors expressing such fusion polypeptides, pharmaceutical compositions comprising the polypeptides or polynucleotides encoding them, host cells for their production, and methods of using such pharmaceutical compositions as vaccines or for generation of antibodies.

ANTIVIRAL PRODRUGS, INTERMEDIATE-AND LONG-ACTING FORMULATIONS, AND METHODS

Absstract of: WO2024159117A1

Compounds and pharmaceutical formulations including a compound and an oil, which may be formulated for intermediate- or long-acting intramuscular injection. Methods for treating respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), coronavirus, SARS CoV-2, and other RNA virus infections in mammals.

SULFONAMIDE-1H-PYRROLE-2-CARBOXAMIDE INHIBITORS OF SARS-COV-2 NSP14 METHYLTRANSFERASE AND DERIVATIVES THEREOF

Absstract of: WO2024158863A1

Methods and compositions for treating SARS-CoV-2 and COVID-19 are disclosed. Sulfonamide-1H-pyrrole-2-carboxamides of the following formula inhibit the SARS-CoV-2 methyltransferase enzyme NSP14 and are therefore useful for treating SARS-CoV-2 and COVID-19.

1,3-INDOLE-PROPANAMIDE INHIBITORS OF SARS-COV-2 PLPRO/NSP3 AND DERIVATIVES THEREOF

Absstract of: WO2024158872A1

Methods and compositions for treating SARS-CoV-2 and COVID-19 are disclosed. 1,3-indole propanamides of the following formula (I) inhibit the SARS-CoV-2 PLpro/NSP3 protein and are therefore useful for treating SARS-CoV-2 and COVID-19.

GENETICALLY MODIFIED CLOSTRIDIUM STRAINS EXPRESSING RECOMBINANT ANTIGENS AND USES THEREOF

Absstract of: US2024254167A1

The present invention relates to genetically modified Clostridium strains that provide improved combinations of functional features useful for several medical applications requiring the preparation and administration of antigens. In particular, clinical grade spores generated from the Clostridium strains described herein can be efficiently prepared, stored, formulated for oral administration, and advantageously used in the prevention and/or treatment of infectious diseases, such as COVID-19.

VIRUS-LIKE PARTICLE VACCINE FOR CORONAVIRUS

Absstract of: US2024252621A1

The present disclosure relates to targeting SARS-CoV-2, in particular, prevalent strains of SARS-CoV-2, and methods of using such vaccines to induce neutralizing antibody levels against SARS-CoV-2.

NUCLEIC ACID VACCINE AGAINST THE SARS-COV-2 CORONAVIRUS

Absstract of: US2024252622A1

The invention relates to an immunogenic or vaccine composition against the 2019 novel coronavirus (SARS-COV-2), comprising a nucleic acid construct encoding a SARS-COV-2 coronavirus Spike (S) protein antigen or a fragment thereof comprising the receptor-binding domain, wherein the nucleic acid construct sequence is codon-optimized for expression in 5 human.

Coronavirus Constructs and Vaccines

Absstract of: US2024252619A1

Disclosed herein are nucleic acid constructs comprising a replication defective Zika virus vector and one or more coronavirus sequences and compositions thereof. The constructs relates to compositions and methods for inducing an immune response against coronavirus antigens due to the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) outbreak. The results herein indicate that these coronavirus constructs are safe and will induce an immune response that may provide protection against coronaviruses.

LIVE-ATTENUATED VIRUS VACCINE

Absstract of: US2024252616A1

This invention relates to a codon deoptimized severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) genome. In particular, embodiments of the invention concern a vaccine comprising live attenuated SARS-COV-2 comprising a partly codon deoptimized viral genome, SARS-COV-2 comprising a partly codon deoptimized viral genome, as well as their use in methods of treatment and prevention of viral infection. The ORF1a region of the viral genome has been codon deoptimized.

COMPOSITIONS AND METHODS FOR INHIBITING AN INFLAMMATORY RESPONSE AND TREATING INFLAMMATORY DISEASES

Absstract of: US2024254166A1

In alternative embodiments, provided are compositions, including products of manufacture and kits, and methods, for inhibiting the ability of neutrophils, or polymorphonuclear leukocytes (PMNs), to release reactive oxygen species (ROS), thus also inhibiting or ameliorating neutrophil (PMN) contribution to an inflammatory response, thus also treating, ameliorating or preventing neutrophil (PMN)-meditated inflammatory-related pathologies such as acute respiratory distress syndrome (ARDS), including ARDS caused by a viral infection such as COVID-19.

ACE2 FUSION PROTEINS AND USES THEREOF

Absstract of: US2024252601A1

The present disclosure provides ACE2 fusion proteins, comprising multimerization moieties linked to ACE2 moieties, that specifically bind to RBD regions of SARS-CoV and/or SARS-CoV-2. The present disclosure further relates to the methods of producing the ACE2 fusion proteins, pharmaceutical compositions comprising of the ACE2 fusion proteins, and methods of use of the ACE2 fusion proteins to treat conditions associated with SARS-CoV and SARS-CoV-2 infections, such as COVID-19.

MINERALOCORTICOID RECEPTOR ANTAGONISTS FOR THE PREVENTION AND/OR TREATMENT OF A CORONAVIRUS INFECTION

Absstract of: US2024252517A1

The present invention relates to a novel therapy for preventing viral spread and/or reducing viral load in a patient and, in particular, a novel therapy for preventing viral spread and/or reducing viral load in a patient suffering with COVID-19. The therapy involves the administration of a mineralocorticoid receptor antagonist such as, for example, spironolactone.

ANTIVIRAL PHARMACEUTICAL COMPOSITION

Absstract of: US2024252529A1

Sulphated polysaccharides for use as an antiviral active ingredient in an antiviral effective amount in a pharmaceutical composition or medicament for the prophylactic or therapeutic intervention of a SARS-CoV-2 infection in a human individual or non-human animal.

COMPOSITIONS CONTAINING VERTEPORFIN, RIBAVIRIN, GEMCITABINE, OR COMBINATIONS THEREOF AND METHODS OF USE FOR TREATING COVID-19, CANCER, OR NON CANCER DISEASES

Absstract of: US2024252525A1

Disclosed are pharmaceutical formulations and methods using Verteporfin, Ribavirin, and/or Gemcitabine for use in the treatment of diseases by various routes of administration including inhalation, intratumoral, topical and/or systemic injection administration. This invention relates more specifically to the use of Verteporfin, Ribavirin, Gemcitabine, and/or combinations thereof as an inhaled dry powder treatment for COVID-19 and/or other lung infections, cancer and other non-cancer applications, which may be followed by other treatment regimens including radiation therapy, photodynamic therapy, and/or sonodynamic therapy. These pharmaceutical compositions containing one or more of Verteporfin, Ribavirin, and Gemcitabine may be included in pharmaceutical kits containing the compositions, and to methods for the treatment of cancer and non-cancer diseases with the active agents of the pharmaceutical compositions. The administering of Verteporfin alone or in combination with Ribavirin and Gemcitabine may be followed or co-administered with photodynamic and/or sonodynamic therapy (PDT/SDT).

METHOD FOR DETECTING ANTI-SARS-COV-2 ANTIBODY, CHIMERIC PROTEIN, POLYNUCLEOTIDE, EXPRESSION VECTOR, HOST CELL, METHOD FOR PRODUCING CHIMERIC PROTEIN, AND REAGENT

Absstract of: US2024255507A1

Disclosed is a method for detecting an anti-SARS-CoV-2 antibody, the method comprising: detecting an antibody against a chimeric protein comprising an amino acid sequence of a receptor binding region of SARS-CoV-2 and an amino acid sequence of a receptor binding region of a coronavirus belonging to Nobecovirus subgenus in a specimen obtained from a subject using the chimeric protein, the chimeric protein being a protein represented by (i) a protein comprising an amino acid sequence set forth in SEQ ID NO: 1 or 2; or (ii) a protein comprising an amino acid sequence having 80% or more of identity to the amino acid sequence set forth in SEQ ID NO: 1 or 2 and binding to an antibody that recognizes the receptor binding region of SARS-CoV-2.

SARS-COV-2 IMMUNOASSAY METHOD AND IMMUNOASSAY KIT

Absstract of: US2024255505A1

The present invention provides an immunoassay method for assaying SARS-CoV-2 in a biological sample, including using two types of monoclonal antibodies or antibody fragments thereof that bind to a peptide fragment having 30 or less consecutive amino acids in a nucleocapsid protein of SARS-CoV-2, wherein the two types of monoclonal antibodies or antibody fragments thereof recognize different epitopes

Anti-BAFF Antibodies for use in a Method of Treatment of Long Covid and/or Post-Acute Sequelae SARS-CoV-2 Infection (PASC)

Absstract of: US2024254247A1

The present disclosure relates to a B lymphocyte Stimulator (BlyS; B-cell activating factor; BAFF) antagonist for use in the treatment of Long Covid and/or post-acute sequelae SARS-COV-2 infection (PASC). Also disclosed is a BlyS antagonist for use in the treatment of an autoimmune condition induced following a viral infection. Such autoimmune conditions may be chronic, such as Long Covid. Also provided is a method for the treatment of an autoimmune condition induced following a viral infection comprising administering to a subject in need thereof a therapeutically effective amount of a BlyS antagonist.

LLAMA-DERIVED NANOBODIES BINDING THE SPIKE PROTEIN OF NOVEL CORONAVIRUS SARS-COV-2 WITH NEUTRALIZING ACTIVITY AND APPLICATION THEREOF

Absstract of: US2024254202A1

This disclosure is related to llama-derived nanobodies of which the corresponding sequences are provided, corresponding to the variable domain (VHH) of llama heavy chain antibodies recognizing epitopes of the Spike protein of SARS-COV-2, some of them, directed to the receptor binding domain, RBD. The nanobodies disclosed herein have important scientific significance and application prospects, they can be labeled or fused with fluorochromes and enzymes to be used as reagents for immunodetection of the virus. Most importantly, the disclosed nanobodies can be used in the development of a bio-drug for the prevention and clinical treatment of infection and diseases caused by SARS-COV-2.

ANTIBODY-BASED ANTIVIRUS COMPOSITIONS AND METHODS OF USE

Absstract of: US2024254203A1

Provided herein are antibody-based antiviruses comprising a fusion protein that comprises a transmembrane polypeptide and an antibody which binds to a surface protein of a virus, wherein the fusion protein is expressed at a valency of at least about 10 copies on a surface of the antivirus, and wherein the antibody neutralizes the virus when expressed within the fusion protein on the surface of the antivirus but does not neutralize the virus when expressed as an isolated antibody. Further provided herein are antibody-based antiviruses for treating a viral infection (e.g., SARS-COV-2).

PROTEIN ANTIGEN-BINDING MOLECULES

Absstract of: US2024254204A1

The present disclosure provides antigen-binding molecule capable of binding to a sarbecovirus spike protein from two or more different sarbecovirus. Nucleic acids, expression 5 vectors, and cells for making and using the same. In particular antigen-binding molecules such as neutralising antibodies capable of inhibiting interaction between the sarbecovirus spike protein and ACE2, thus behaving as antagonists of infection of ACE2-expressing cells by the sarbecovirus. Antigen-binding molecules described herein are provided with a combination of advantageous properties over known SARS-COV-2 antibodies.

OMICRON CORONAVIRUS VACCINE CONSTRUCTS AND METHODS OF MAKING AND USING SAME

Absstract of: AU2023216258A1

Provided herein are adenoviral vectors encoding spike protein variants of SARS-CoV2 coronavirus, and compositions comprising the vectors. Also provided are methods of prevention and treatment of SARS-CoV2 using the compositions provided.

Products of manufacture and methods for treating, ameliorating or preventing coronavirus infection

Absstract of: AU2024204821A1

PRODUCTS OF MANUFACTURE AND METHODS FOR TREATING, AMELIORATING OR PREVENTING CORONAVIRUS INFECTION Abstract Therapeutic agents, combination therapies, and methods for the treatment of coronavirus infections and associated diseases, particularly COVID-19, are provided. The provided therapeutics include oseltamivir, lopinavir, ritonavir, chloroquine or hydroxychloroquine, azithromycin, clarithromycin, doxycycline, ivermectin, and combinationsthereof.

Anti-sars-cov-2 spike (s) antibodies and their use in treating covid-19

Absstract of: AU2022420026A1

Infectious diseases remain a problem throughout the world. The outbreak of sudden acute respiratory syndrome coronavirus 2 (SARS-Co V-2) has infected more than 640 million people worldwide. SARS-Co V-2 causes the disease COVID-19. Mutations in the SARS-CoV-2 S spike protein enable SARS-CoV-2 variants to escape neutralizing monoclonal antibodies produced from previous infection with SARS-CoV2 or by vaccination. The present invention provides antibodies that bind to the SARS-Co V-2 Spike (S) protein. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using the aforementioned antibodies that bind to the SARS-CoV-2 Spike (S) protein.

SARS-CoV-2 TIS-L TIS-L targeting Antiviral Antisense Oligonucleotide with ability to inhibit viral replication of SARS-CoV-2

Absstract of: KR102690306B1

본 발명은 SARS-CoV-2 증식을 억제하는 TIS-L 표적 안티센스 올리고뉴클레오타이드 및 이의 항 바이러스 용도에 관한 것이다. 본 발명에 따른 TIS-L 표적 안티센스 올리고뉴클레오타이드는 구조가 간단하여 대량 생산이 용이하고, 원형주 및 다양한 변형주 바이러스에서 적은 용량으로도 90% 이상의 항바이러스 효능을 나타내는 바, COVID-19 치료제 개발에 유용하게 활용될 수 있다.

RIBONUCLEOSIDE ANALOGUES AGAINST -SARS-COV-2

Absstract of: WO2023046900A1

The invention relates to nucleoside derivatives of formula (I), wherein R has the same meaning as that defined in the claims and the description. The present invention also relates to pharmaceutical compositions comprising such compounds and to uses of such compounds and compositions for the treatment or prevention of viral infections, more in particular infections caused by RNA virus, such as coronavirus infections.

METHOD AND DEVICE FOR INACTIVATING NOVEL CORONAVIRUS

Absstract of: EP4406561A1

Provided are a new coronavirus inactivation method and a new coronavirus inactivation device that are capable of quick inactivation, are safe, and are practical.The new coronavirus inactivation device is a device for inactivating new coronavirus SARS-CoV-2 by singlet oxygen, the device including: a contactor configured to bring an aqueous rose bengal solution and air containing the new coronavirus SARS-CoV-2 into contact with each other in a state where light is applied to the aqueous rose bengal solution, wherein the aqueous rose bengal solution has a concentration of not less than 10 µM and not greater than 50 µM, and the light applied to the aqueous rose bengal solution has an illuminance of not less than 500 lux and not greater than 8000 lux.

CORONAVIRUS VACCINE

Absstract of: ZA202210524B

This disclosure relates to the field of RNA to prevent or treat coronavirus infection. In particular, the present disclosure relates to methods and agents for vaccination against coronavirus infection and inducing effective coronavirus antigen-specific immune responses such as antibody and/or T cell responses. These methods and agents are, in particular, useful for the prevention or treatment of coronavirus infection. Administration of RNA disclosed herein to a subject can protect the subject against coronavirus infection. Specifically, in one embodiment, the present disclosure relates to methods comprising administering to a subject RNA encoding a peptide or protein comprising an epitope of SARS-CoV-2 spike protein (S protein) for inducing an immune response against coronavirus S protein, in particular S protein of SARS-CoV-2, in the subject, i.e., vaccine RNA encoding vaccine antigen. Administering to the subject RNA encoding vaccine antigen may provide (following expression of the RNA by appropriate target cells) vaccine antigen for inducing an immune response against vaccine antigen (and disease-associated antigen) in the subject. In December 2019, a pneumonia outbreak of unknown cause occurred in Wuhan, China and it became clear that a novel coronavirus (severe acute respiratory syndrome coronavirus 2; SARS-CoV-2) was the underlying cause. The genetic sequence of SARS-CoV-2 became available to the WHO and public (MN908947.3) and the virus was categorized into the betacor

COMPOSITION FOR TREATING CORONAVIRUS DISEASE 2019 (COVID-19) CONTAINING TAURODEOXYCHOLIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND ANTIVIRAL AGENT AS ACTIVE INGREDIENTS

Absstract of: EP4406540A1

The present invention relates to a composition for treating coronavirus infection-19 (COVID-19), comprising taurodeoxycholic acid (TDCA) or a pharmaceutically acceptable salt thereof and an antiviral agent as active ingredients, it was confirmed that clinical symptoms were cured in patients with COVID-19 pneumonia who were administered a combination of a pharmaceutically acceptable salt of taurodeoxycholic acid as an inflammasome inhibitor and an antiviral agent, and thus this combination of taurodeoxycholic acid (TDCA) or a pharmaceutically acceptable salt thereof as an inflammasome inhibitor and an antiviral agent, holds promise as active ingredients in compositions for the prevention or treatment of lower respiratory tract infectious diseases, including COVID-19.

RECOMBINANT VACCINE AGAINST COVID-19 TO PRODUCE CELLULAR RESPONSE IN INDIVIDUALS WITH PRE-EXISTING IMMUNITY

Absstract of: CA3230865A1

A recombinant vaccine is described, which comprises an active Newcastle disease viral vector (NDV) having inserted an exogenous nucleotide sequence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), without adjuvant, capable of generating a significant cellular response in T cells (CD4+ or CD8+) when stimulated with the S protein of the SARS-CoV-2 virus or proteins derived from it in individuals with previous immunity.

SARS-COV-2 RNA VACCINE COMPOSITIONS AND METHODS OF USE

Absstract of: AU2022349251A1

The disclosure provides compositions, methods of treatment, and methods of making and using compositions to deliver a nucleic acid to a subject. Compositions described herein include lipid carriers, optionally including an inorganic particle, capable of admixing with nucleic acids. Methods of using the compositions as a COVID-19 vaccine for the treatment of a coronavirus infection are also provided.

Kit and method for detecting infection, especially with SARS-CoV-2 virus, using in situ hybridization

Absstract of: PL443616A1

Zestaw do wykrywaniu zakażenia, zwłaszcza wirusem SARS-CoV-2, przy użyciu hybrydyzacji in situ, charakteryzuje się tym, że zawiera: - oligonukleotydową sondę hybrydyzacyjną specyficzną wobec genomu patogenu wywołującego zakażenie lub produktu transkrypcji tego genomu, zwłaszcza genu wirusa SARS-CoV-2 lub produktu transkrypcji tego genu wybranego spośród: E1, E2, E3, N1, N2, N3, ORFlab1, ORFlab2, ORFlab3 oraz produktów transkrypcji tych genów, - znakowaną, zwłaszcza fluorescencyjnie, sondę hybrydyzacyjną, przy czym wspomniana oligonukleotydowa sonda hybrydyzacyjna, specyficzna wobec genomu patogenu wywołującego zakażenie lub produktu transkrypcji tego genomu, posiada na obydwu swoich końcach sekwencję nukleotydową komplementarną do znakowanej sondy hybrydyzacyjnej. Przedmiotem zgłoszenia jest również sposób wykrywaniu zakażenia wirusem SARS-CoV-2 przy użyciu hybrydyzacji in situ.

How to assess the risk of severe COVID-19

Absstract of: PL443593A1

Przedmiotem zgłoszenia jest sposób oceny ryzyka ciężkiego przebiegu COVID-19, w którym dokonuje się oceny poziomu pozawątrobowej witaminy K1 w krwi, osoczu lub surowicy, przy czym jeśli poziom witaminy K1 jest niższy niż 1,0 nmol/dm<3>, to uznaje się, że występuje wysokie ryzyko ciężkiego przebiegu COVID-19.

Method of determining the level of risk of severe COVID-19 disease in a patient

Absstract of: PL446346A1

Ujawniono sposób badania obecności dwóch polimorfizmów genetycznych, których występowanie istotnie modyfikuje przebieg choroby COVID-19, sposób ten stanowi nowe narzędzie w ochronie populacji przed chorobą COVID-19.

REAL-TIME BREATH ANTIGEN DETECTION SYSTEM AND METHOD THEREOF

Absstract of: AU2023213096A1

The invention relates to a system for antigen detection comprising a first container configured to collect aerosols out of exhaled air of a human and a second container suitable for a solvent, wherein nanoparticles are dissolved in the solvent and the nanoparticles are linked to antibodies, further wherein a change of optical properties of the solvent is detectable upon contact between the antibodies and matching antigens. Here, a person can exhale air into the first container, and the aerosols exhaled in the air stick in a filter on one side of the first container. Thereupon, the first container is incooperable in the second container, in which a solvent with nanoparticles dissolved therein and antibodies coupled thereto are located. The incooperability, in particular a shuttling stroke motion, flushes the aerosols into the solvent. If antigens matching the antibodies are present on the aerosols, the nanoparticles agglomerate around the antigen, changing the optical properties of the solvent, which is irradiated by a light source and detectable by a light sensor. In further aspects, the invention relates to a method using the system according to the invention. The invention further relates to corresponding medical uses and therapeutic methods of administering a prevention of a medical condition associated with a SARS Coronavirus, in addition to diagnostic uses and methods.

RECOMBINANT NEWCASTLE DISEASE VIRUSES AND IMMUNOGENIC COMPOSITIONS FOR USE IN PREVENTING COVID-19

Absstract of: AU2023231285A1

Described herein are recombinant Newcastle disease viruses ("NDVs") comprising a packaged genome, wherein the packaged genome comprises a transgene comprising a nucleotide sequence encoding a protein comprising a SARS-CoV-2 spike protein or portion thereof. Also described herein are recombinant NDVs comprising a packaged genome, wherein the packaged genome comprises a transgene encoding a chimeric F protein, wherein the chimeric F protein comprises a SARS-CoV-2 spike protein ectodomain and NOV F protein transmembrane and cytoplasmic domains. Further, described herein are immunogenic compositions comprising a recombinant NDV(s). The recombinant NDVs and immunogenic compositions are useful for the immunizing against SARS-CoV-2 as well as the prevention of CO VID-19.

ANTIBODY SPECIFICALLY BINDING TO IL-10 RECEPTOR AND USE THEREOF

Absstract of: WO2024154958A1

The present invention relates to an antibody specifically binding to an IL-10 receptor and use thereof. The antibody targets IL-10 signaling and has an excellent effect of suppressing cytokine storm and excessive inflammation in severe inflammatory infectious diseases, and in particular, can be effectively used in suppressing inflammatory responses in severe SARS-CoV-2 infection and fatal SFTSV infection.

USE OF GAMMA PRIME FIBRINOGEN AS A BIOMARKER IN THE ASSESSMENT FOR TREATMENT OF COVID-19 INFECTIONS AND LONG COVID-19

Absstract of: WO2024154045A1

A method is provided for treating a subject with an alternative therapeutic agent to heparin including a non-heparin anticoagulant, wherein the subject has been infected with COVID-19 or has symptoms of long COVID-19 post infection with COVID-19, the method comprising the steps of: obtaining or having obtained a sample from the subject, determining levels of GPF in the sample are above a reference range, and administering the alternative therapeutic agent to the subject if the GPF levels in the sample indicate the subject is heparin resistant, and wherein the alternative therapeutic agent preferably prevents activation of thrombin or reduces levels of active thrombin.

USE OF CPG ADJUVANT IN PREPARATION OF NOVEL CORONAVIRUS VACCINE

Absstract of: WO2024152998A1

Use of a CpG adjuvant in the preparation of a novel coronavirus vaccine. Provided is a composite adjuvant, comprising the CpG adjuvant and an A1 adjuvant. The nucleotide sequence of the CpG adjuvant is SEQ ID NOs: 1-5. Provided is a novel coronavirus vaccine, consisting of a novel coronavirus antigen, and the CpG adjuvant and the A1 adjuvant in a first aspect. Provided is a composition (vaccine) for stimulating or eliciting an immune response against SARS-CoV-2. The immune response includes, but is not limited to, an immune response that generates a neutralizing antibody against SARS-CoV-2 and is biased towards Thl. CpGODN is a fully phosphorothioated oligodeoxynucleotide containing non-methylated CG dinucleotide (CpG) linked by phosphorus (p), and has an immunostimulatory effect.

PROTEIN AND VACCINE FOR RESISTING INFECTION FROM SARS-COV-2 OMICRON MUTANT STRAIN AND SUBTYPE THEREOF

Absstract of: WO2024152844A1

The present invention relates to the field of medicines, and relates to a protein and vaccine for resisting infection from a SARS-CoV-2 Omicron mutant strain and a subtype thereof. In order to solve the problem of lack of drugs for effective prevention and treatment for infections from the SARS-CoV-2 Omicron mutant strain and the subtype thereof, the present invention provides the protein and the vaccine for resisting infection from the SARS-CoV-2 Omicron mutant strain and the subtype thereof. The vaccine is optimally designed on the basis of an RBD sequence in an S protein of the SARS-CoV-2 Omicron mutant strain and substrains BA.4/5, BQ.1.1, and XBB.1.5, can help a host to resist a coronavirus infection, and particularly has a relatively good prevention and treatment effect on a cross infection caused by a SARS-CoV-2 Omicron mutant strain and subtype viruses thereof.

MEDICATED DIET COMPOSITION FOR TREATING HEAT COUGH, AND PREPARATION METHOD THEREFOR AND USE THEREOF

Absstract of: WO2024153265A1

A medicated diet composition for treating a heat cough, prepared from the raw materials in the following parts by mass: 50-100 parts of kumquat, 30-50 parts of Eleocharis dulcis, 5-10 parts of Glehniae radix and 5-10 parts of Platycodonis radix. The medicated diet composition can improve the symptoms of a heat cough of a SARS-CoV-2 infection.

PREPARATION AND USE OF MRNA VACCINE AND RECOMBINANT PROTEIN SUBUNIT VACCINE AGAINST SARS-COV-2 OR MUTANT

Absstract of: WO2024152845A1

Provided in the present invention is a recombinant protein vaccine and/or an mRNA vaccine for preventing and/or treating infections of SARS-CoV-2 or a mutant thereof, and particularly provided is a method of using the mRNA vaccine and the recombinant protein vaccine. The vaccine can induce the generation of an antibody response and a cellular immune response in vivo to block the binding of the S protein of SARS-CoV-2 to the ACE2 receptor of host cells, so that the host resists coronavirus infections.

MEDICATED DIET COMPOSITION FOR TREATING COLD COUGH, AND PREPARATION METHOD THEREFOR AND USE THEREOF

Absstract of: WO2024153266A1

The present invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a medicated diet composition for treating a cold cough, and a preparation method therefor and the use thereof. The medicated diet composition of the present invention comprises the raw materials in the following parts by mass: 50-100 parts of kumquat, 10-20 parts of fresh ginger, 2-3 parts of Citri reticulatae pericarpium and 5-10 parts of Platycodonis radix. The medicated diet composition of the present invention can quickly improve the symptoms of a cold cough of a SARS-CoV-2 infection, and is particularly suitable for patients with a cold cough of a SARS-CoV-2 infection in regions where drug resources are relatively short, medical resources are relatively poor and the purchase of drugs is relatively difficult.

METHODS AND COMPOSITIONS FOR DETECTING SARS-COV2 VIRUS OMICRON, ALPHA, BETA, DELTA, OR GAMMA

Absstract of: US2024247322A1

The present invention concerns methods for detecting SARS-CoV 2 virus omicron, alpha, beta, delta and/or gamma as well as kits for performing such methods.

SARS-COV-2 RBD CONSTRUCTS

Absstract of: US2024247033A1

The present invention relates to glycan-masked and membrane-tethered SARS-CoV-2 RBD vaccine constructs and methods for making and administering the same. The present invention also encompasses a general vaccine platform for coronaviruses.

PORTABLE HYPERBARIC OXYGEN (PHBO) HOOD FOR COVID-19 PATIENTS

Absstract of: US2024245875A1

A portable hyperbaric oxygen (PHBO) hood system includes a main hood, a neck sleeve configured to be disposed below the main hood, a pump system configured to control a pressure in the main hood to create hyperbaric environment in the PHBO hood system, and an intelligent controller. The pump system includes a pump and a flow line configured to supply oxygen to the main hood via the pump. The intelligent controller is configured to receive an oxygen saturation value of a patient, receive an oxygen concentration value of the flow line, determine a target pressure of the main hood based on the oxygen saturation value and the oxygen concentration value, and control the pump system to change the pressure of the main hood to the target pressure.

INTRANASAL ADMINSTRATION OF CANNABIGEROL, CBDa, CBGa, & UNCARIA TOMENTOSA HYDROALCOHOLIC EXTRACT COMPOUNDS EMULSIFIED IN SALINE HOMOGENOUS SOLUTION FOR INTRANASAL ADMINISTRATION

Absstract of: US2024245744A1

The therapeutic product invention states to the use of quantified solutions containing natural compounds of cannabidiol, CBDa, cannabigerol, CBGa combined with Uncaria tomentosas' hydroalcoholic extracts emulsified in saline solution in homogenous mixture administered intranasally. A natural respiratory immune booster with mechanisms against respiratory viruses and foreign substances (e.g. SARS-Cov-2 spike protein, bacterial, allergen) including; inhibition, reduction, blockage of cellular entry, and encapsulation and expulsion with minute impact of variant lineage. By induction of the interferon pathway both directly and indirectly following activation of the host immune response to viral pathogen, suppressing cytokine activation in response to viral infection, as well as blocks viral replication after entry into cells. Attaching to viral protein, mechanically inhibiting the SARS-COV-2 enzyme 3CLpro and disrupts the interface of the receptor-binding domain of angiotensin-converting enzyme 2 (RBD-ACE-2) as well as the SARS-COV-2 spike glycoprotein.

AGENT FOR TREATING INFECTIOUS DISEASES AGAINST MUTANT VIRUSES OF NOVEL CORONAVIRUS

Absstract of: US2024245679A1

This agent for treating coronavirus infectious diseases caused by mutant viruses of SARS-COV-2 contains, as an active ingredient, 6-fluoro-3-hydroxy-2-pyrazinecarboxamide or a salt thereof.

ANTISENSE MOLECULES AND THEIR USES FOR THE TREATMENT OF CORONAVIRUS INFECTION, IN PARTICULAR THE TREATMENT OF COVID-19 RELATED TO SARS-COV-2 INFECTION

Absstract of: WO2024153586A1

The present invention relates to a new antisense oligonucleotide, a pharmaceutical composition comprising it and their use for preventing or treating infection by coronavirus, especially by SARS-CoV-2 virus which causes the infection disease COVID-19.

ANTIVIRAL PRODRUGS, INTERMEDIATE- AND LONG-ACTING FORMULATIONS AND METHODS

Absstract of: AU2023213682A1

Compounds and pharmaceutical formulations including a compound and an oil, which may be formulated for intermediate- or long-acting intramuscular injection. Methods for treating respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), coronavirus, SARS CoV-2, and other RNA virus infections in mammals.

ANTIBODIES AGAINST SARS-COV-2 AND USES THEREOF IN THE MEDICAL FIELD

Absstract of: WO2023042235A1

The present invention relates to antibodies against SARS-CoV-2 and uses thereof in the medical field for the prevention and treatment of SARS-CoV-2 infection and COVID-19 disease.

NEW COMBINATION DRUG FOR TREATING CORONAVIRUS INFECTIONS, PHARMACEUTICAL COMPOSITION AND USE THEREOF

Absstract of: EP4403177A1

The present invention provides a new combinatorial drug or a new pharmaceutical composition comprising nitazoxanide, atovaquone and/or ribavirin, and their use for the treatment or prevention of coronavirus infections, particularly the use for the treatment or prevention of infections caused by SARS-CoV-2 and mutants thereof.

SYNTHETIC HUMANIZED LLAMA NANOBODY LIBRARY AND USE THEREOF TO IDENTIFY SARS-COV-2 NEUTRALIZING ANTIBODIES

Absstract of: AU2022345251A1

Methods for producing synthetic single-domain monoclonal antibody libraries using humanized llama nanobody framework sequences, libraries obtainable by the method, as well as antibodies selected from the libraries are described. In particular, synthetic single-domain monoclonal antibodies that specifically bind to the spike protein of SARS-CoV-2 and neutralize SARS-CoV-2 infection are described. Use of the disclosed antibodies for the detection, prophylaxis and treatment of SARS-CoV-2 infection is described.

COMPOUNDS AND METHODS FOR TREATING DISEASES CAUSED BY SARS-COV-2 AND OTHER CORONAVIRUSES

Absstract of: WO2024151953A1

Provided are compounds and methods of treating diseases caused by a Coronaviridae virus such as SARS-CoV-2, SARS-CoV, and MERS-CoV coronaviruses by administering nitrogen-containing heterocyclic compounds. SARS (Severe Acute Respiratory Syndrome), MERS (Middle East Respiratory Syndrome), and, particularly, COVID-19 are highly contagious diseases with high mortality rate responsible for tens of millions of infections and almost two million deaths around the globe.

SARS-COV2 MAIN PROTEASE INHIBITORS

Absstract of: US2024239807A1

The present disclosure relates to compounds of Formula I:and pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof, useful in the treatment of treating viral infections, for example, coronaviridae infections.

THERAPEUTICS DIRECTED AGAINST CORONAVIRUS

Absstract of: US2024238437A1

This invention provides compositions and methods to treat, prevent, and diagnose viral infections. The methods provided herein involve administering polypeptides of the invention to a subject in need thereof. The viral infections can be caused by a coronavirus such as SARS-CoV-1, SARS-CoV-2 or a variant thereof. It is contemplated that the polypeptide can be further linked to a compound, wherein the compound extends the serum half-life of the polypeptide.

PHARMACEUTICAL FOR TREATING NOVEL CORONAVIRUS INFECTION

Absstract of: AU2023202177A1

The present invention provides a pharmaceutical composition containing a coronavirus 3CL protease inhibitor in order to treat a novel coronavirus (COVID-19) infection. Provided is a pharmaceutical composition for treating a novel coronavirus (COVID-19) infection, said pharmaceutical composition containing, as an effective ingredient, a composite that includes a compound represented by formula (I) and fumaric acid.

A LIVE ATTENUATED SARS-COV-2 AND A VACCINE MADE THEREOF

Absstract of: AU2022435931A1

The invention relates to a polynucleotide encoding a) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein; and/or b) at least one non-structural SARS-CoV-2 protein selected from the group consisting of non-structural protein (7), non-structural protein (8), non-structural protein (9), non-structural protein (10), non-structural protein (11), non-structural protein (12), an endoribonuclease, and a 2'-O-methyltransferase, wherein the polynucleotide comprises or consists of at least one sequence part comprising codon-pair deoptimizations in comparison to the SARS-CoV-2 genome. The invention further relates to a live attenuated SARS-CoV-2 comprising this polynucleotide, to a vaccine comprising this live attenuated SARS-CoV-2, as well as to associated methods.

SARS-COV-2 MULTI-EPITOPE VACCINES

Absstract of: US2024238409A1

The present invention provides multi-epitope vaccines comprising or capable of expressing one or more concatemers of epitopes from a viral pathogen, namely, SARS-COV-2. wherein at least a portion of the epitopes are from conserved viral proteins and wherein the vaccine comprises or expresses epitopes for all MHC I and MHC II alleles with a frequency >1% in the target population.

CORONAVIRUS ANTIBODIES AND THERAPEUTIC USES THEREOF

Absstract of: WO2024150074A2

Disclosed herein are antibodies that bind to coronavirus spike protein (e.g., SARS-CoV-2 spike protein), and methods of use thereof (e.g., treatment of subjects infected with SARSCoV-2).

VACCINES AND RELATED METHODS

Absstract of: WO2024151583A2

Provided herein are SARS-CoV-2 spike proteins and polypeptides (e.g., SARS-CoV-2 spike proteins and polypeptide immunogens (and immunogenic fragments and immunogenic variants thereof)) comprising at least one set of amino acid substitutions, and nucleic acid molecules encoding the same. Further provided herein are compositions (e.g., pharmaceutical compositions) and vaccines comprising the same for use in e.g., the prevention, treatment, and/or amelioration of a SARS-CoV-2 infection; vaccination against SARS-CoV-2.

ADJUVANTED INACTIVATED RECOMBINANT RABIES VIRUS VECTORED CORONAVIRUS VACCINE FORMULATIONS

Absstract of: US2024238411A1

The invention discloses an adjuvanted inactivated recombinant rabies virus vectored coronavirus vaccine formulation comprising SEPIVAC SWE or MemVax as adjuvant/s. The invention provides vaccine compositions, formulation 1 comprising combination of inactivated recombinant rabies virus vectored antigen and SEPIVAC SWE as an adjuvant and formulation 2 comprising combination of inactivated recombinant rabies virus vectored antigen and MemVax as an adjuvant. The said adjuvanted inactivated recombinant rabies virus vectored (rDNA-CoroRab) vaccine formulation prepared using SEPIVAC SWE or MemVax induces robust humoral, and cell mediated responses against SARS-CoV-2 compared to antigen alone and provides long term immunity.

MODIFIED NUCLEOSIDES AND NUCLEOTIDES ANALOGS AS ANTIVIRAL AGENTS FOR CORONA AND OTHER VIRUSES

Absstract of: US2024238323A1

Compounds, compositions and methods for preventing, treating or curing a coronavirus infection in human subjects or other animal hosts. In one embodiment, the compounds can be used to treat an infection with a severe acute respiratory syndrome virus, such as human coronavirus 229E, SARS, MERS, SARS-CoV-1 (OC43), and SARS-CoV-2. In another embodiment, the methods are used to treat a patient infected with a Flavivirus, Picornavus, Togavirus, or Bunyavirus.

PHARMACEUTICLA COMPOSITION FOR PREVENTION OR TREATMENT OF VIRUS-INDUCED DISEASE

Absstract of: US2024238359A1

A pharmaceutical composition for use in the treatment or prevention of SARS Covid 19, wherein the composition includes an extract of Trigonella foenum-graecum and optionally pharmaceutically acceptable additives.

HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19

Absstract of: US2024238324A1

The present invention is the use of a small group of purine nucleotide phosphoramidate disclosed herein or a pharmaceutically acceptable salt thereof in an effective amount for the treatment or prevention of the novel 2019 coronavirus disease (COVID-19) in a host, for example a human, in need thereof.

TAPENTADOL FOR TREATING NEUROPATHIC PAIN IN COVID-19 PATIENTS

Absstract of: US2024238221A1

The invention relates to a pharmaceutical dosage form comprising Tapentadol or a physiologically acceptable salt thereof for use in the treatment of pain in a patient who is or who was previously infected with a coronavirus.

USE OF CLOFOCTOL FOR THE TREATMENT OF INFLAMMATION

Absstract of: US2024238217A1

There is a need for novel therapies for the treatment of inflammation. Now, the inventors surprisingly show that clofoctol has potent anti-inflammatory properties. In particular, the inventors demonstrate that clofoctol treatment drastically reduced pulmonary inflammation in two models that recapitulate severe inflammation, one induced by the virus SARS-COV-2, and the other induced by LPS. Collectively, the data of the inventors justify to suggest that clofoctol would be suitable for the treatment of inflammation in general.

USE OF A COMPOUND SUCH AS PLERIXAFOR FOR TREATING A VIRAL PULMONARY DISEASE

Absstract of: US2024238244A1

A compound of formula (I) or a pharmaceutically acceptable salt and/or hydrate thereof, for use in the treatment of a viral pulmonary disease or a chronic respiratory distress syndrome (CRDS) resulting from a viral pulmonary disease in a subject, the disease being different from COVID-19, wherein formula (I) is Z—R-A-R′—Y, including plerixafor.

BRET-BASED CORONAVIRUS MPRO PROTEASE SENSOR AND USES THEREOF

Absstract of: US2024240228A1

The SARS-CoV-2 main protease, MPRO, is critical for its replication and is an appealing target for designing anti-SARS-CoV-2 agents. In this regard, a number of assays have been developed based on its cleavage sequence preferences to monitor its activity. These include the usage of Fluorescence Resonance Energy Transfer (FRET)-based substrates in vitro and a FlipGFP reporter, one which fluoresces after MPRO-mediated cleavage, in live cells. Here, a pair of genetically encoded, Bioluminescence Resonance Energy Transfer (BRET)-based sensors have been engineered for detecting SARS-CoV-2 MPRO proteolytic activity in living host cells. The sensors were generated by sandwiching MPRO N-terminal autocleavage sites, either AVLQSGFR (short) or KTSAVLQSGFRKME (long), in between the mNeonGreen and nanoLuc proteins. Co-expression of the sensor with the MPRO in live cells resulted in its cleavage in a dose-dependent manner while mutation of the critical C145 residue (C145A) in MPRO completely abrogated the sensor cleavage. A temporal activity of MPRO in live cells and its inhibition was shown using the well-characterized pharmacological agent GC376. The sensor developed here finds direct utility in studies related to drug discovery targeting the SARS-CoV-2 MPRO and functional genomics application to determine the effect of sequence variation in MPRO Importantly, the BRET-based sensors displayed increased sensitivities and specificities as compared to the recently developed FlipGFP-based MP

TAQ-NEQSSB POLYMERASE, THE METHOD OF ITS OBTAINING, RECOMBINANT PLASMID, PRIMERS, AND APPLICATION OF THE POLYMERASE

Absstract of: US2024240163A1

The subject of the invention is a TaqPol-NeqSSB polymerase and its cloning method. Furthermore, the subject of the invention is an isolated recombinant plasmid, primers, and the application of the polymerase to replicate specific sequences of the SARS CoV-2 virus.

SARS-COV-2 SPIKE PROTEIN ANTIBODIES

Absstract of: US2024239875A1

The present disclosure provides antibodies that bind to the SARS-CoV-2 spike protein, as well as compositions containing the same, and methods of making and using such a composition for treating, preventing, and/or detecting SARS-CoV-2 infection.

APPLICATIONS OF ANALOGS OR DERIVATIVES OF SIALIC ACIDS

Absstract of: US2024239829A1

Provided are compositions or products comprising analogs or derivatives of N-acetylneuraminic acid with a particular pH range. The compositions or products are effective for treating or preventing highly pathogenic viral infections such as COVID-19 infection, the serious adverse reactions of vaccines, and infection-relating autoimmune diseases including COVID-19 long haulers. More specifically, the present disclosure relates to the methods of preparing the compositions or the products. Products can be implemented as a therapeutic product, a nutritional supplement, a food, a feed, a food additive, a feed additive, a rehydration salt, or a rehydration solution.

PROTEASE INHIBITORS AND METHODS OF USE

Absstract of: US2024239772A1

Disclosed herein are compounds that inhibit 3C-like protease and inhibit replication of viruses, including SARS-CoV-2. Also disclosed herein are pharmaceutical compositions comprising the compounds, and methods of using the compounds, e.g., in a method of treating a viral infection, such as a coronavirus infection.

SYSTEM FOR ASSISTING WITH PROVISION OF DIAGNOSTIC INFORMATION

Absstract of: US2024242790A1

The present invention relates to a system (1) for assisting with provision of diagnostic information, especially with a view to detecting a disease in a person, especially a contagious disease such as COVID-19, this detecting system comprising: —a device (7) for acquiring examination data on the person, this acquiring device especially comprising, to acquire these examination data, at least a sensor, such as a radar, for measuring physiology and a thermal camera, this acquiring device comprising a plurality of sensors arranged to operate without contact with the person, at least one of the contactless sensors being arranged to acquire a response datum provided by the person.

SARS-COV-2 IMMUNOASSAY METHOD AND IMMUNOASSAY KIT, AND MONOCLONAL ANTIBODY OR ANTIBODY FRAGMENT THEREOF

Absstract of: US2024241120A1

The present invention provides an immunoassay method for assaying SARS-CoV-2, including a step of contacting a biological sample with a monoclonal antibody or an antibody fragment thereof that binds to a nucleocapsid protein of SARS-COV-2, wherein the monoclonal antibody or the antibody fragment thereof binds to the SARS-CoV-2 treated with a serine protease.

PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION

Absstract of: WO2024151465A1

The present invention provides a compound of Formula I wherein R1, R2, R3, R4, R5, R6, R7, and subscripts X and n are as described herein and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for the treatment, inhibition, or amelioration of one or more disease states that could benefit from inhibition of a coronavirus, including SARS-CoV, MERS-CoV and SARS-CoV-2. The compounds of this invention could further be used in combination with other therapeutically effective agents, including but not limited to, other drugs useful for the treatment of coronavirus infection. The invention furthermore relates to processes for preparing compounds of Formula I, and pharmaceutical compositions which comprise compounds of Formula I and pharmaceutically acceptable salts thereof.

ANTIVIRAL STRUCTURALLY-STAPLED SARS-COV-2 PEPTIDE- CHOLESTEROL CONJUGATES AND USES THEREOF

Absstract of: AU2022341116A1

Disclosed herein are cross-linked peptides either alone or conjugated to PEG(n)-cholesterol (or thiocholesterol) moieties useful for interfering with and inhibiting or preventing coronavirus infection (e.g., infection by SARS-CoV-2). Also disclosed are methods of treating and/or preventing a coronavirus infection (e.g., COVID-19.

USE OF COMPOUND ATV014 FOR RESISTING SARS-COV-2 INFECTION

Absstract of: WO2024146588A1

The use of compound ATV014 or a pharmaceutically acceptable salt thereof or a crystalline hydrate thereof or a solvate thereof in the preparation of a product for the prevention, remission or treatment of SARS-CoV-2 omicron strain infection, or the replication or reproduction of a homologous variant virus thereof and a cytopathic effect caused thereby. The present invention relates to the technical field of pharmaceutical technology and viral infectious diseases. The structural formula of the compound ATV014 is as follows:

PROTEASE INHIBITORS AND METHODS OF MAKING SAME

Absstract of: US2024228460A1

Inhibitors of the SARS-CoV-2 Mpro protease and methods of their use in treating a coronavirus infection in a subject are provided. The inhibitors may have the general structure (I):

ANTI-SARS-CoV-2 SPIKE (S) ANTIBODIES AND THEIR USE IN TREATING COVID-19

Absstract of: AU2022420026A1

Infectious diseases remain a problem throughout the world. The outbreak of sudden acute respiratory syndrome coronavirus 2 (SARS-Co V-2) has infected more than 640 million people worldwide. SARS-Co V-2 causes the disease COVID-19. Mutations in the SARS-CoV-2 S spike protein enable SARS-CoV-2 variants to escape neutralizing monoclonal antibodies produced from previous infection with SARS-CoV2 or by vaccination. The present invention provides antibodies that bind to the SARS-Co V-2 Spike (S) protein. The invention further relates to pharmaceutical compositions, immunotherapeutic compositions, and methods using the aforementioned antibodies that bind to the SARS-CoV-2 Spike (S) protein.

RECOMBINANT VIRAL CLASS I FUSION PROTEINS AND USES THEREOF

Absstract of: US2024226274A1

Recombinant viral class I fusion proteins that favor a prefusion conformational state over a postfusion conformational state, polynucleotides encoding same, vaccines comprising the proteins or polynucleotides, and methods of vaccination with the vaccines. The recombinant proteins include recombinant RSV F proteins, recombinant hMPV proteins, and recombinant SARS-COV-2 S proteins.

Nant COVID Vaccine Cross Reactivity

Absstract of: US2024226282A1

Recombinant SARS-CoV2 vaccine compositions and methods are presented that have unexpected cross-reactivity against a variety of other coronaviruses, and particularly against SARS-CoV1, MERS-CoV, OC43-CoV, and HKU1-CoV in addition to significant reactivity against SARS-CoV2A. Moreover, the vaccine compositions presented herein also produced cross-reactive memory B cells as well as cross-reactive memory T cells with cross-reactivity spanning a relatively wide range of different coronaviruses.

HUMAN ANTI-CORONAVIRUS PEPTIDE VACCINES AND METHODS OF THEIR USE

Absstract of: US2024226279A1

Disclosed are compositions related to modified coronavirus S protein peptides, synthetic coronavirus S protein peptides, chimeric coronavirus S protein peptides, anti-coronavirus S protein antibodies and methods of treating coronavirus infections using said peptides or antibodies.

LIPOPEPTIDE FUSION INHIBITORS AS SARS-COV-2 ANTIVIRALS

Absstract of: US2024226304A1

Described herein is a composition and method of preventing COVID-19 with lipid-peptide fusion antiviral therapy.

INFLUENZA-CORONAVIRUS COMBINATION VACCINES

Absstract of: US2024226277A1

The disclosure provides combination miRNA vaccines for respiratory viruses, such as influenza and coronaviruses (e.g., SARS-CoV-2) as well as methods of using the vaccines.

PROBIOTIC COMPOSITION FOR THE TREATMENT OF COVID-19

Absstract of: US2024226199A1

A probiotic composition comprising Lactobacillus plantarum CECT 30292, Lactobacillus plantarum CECT 7484, Lactobacillus plantarum CECT 7485, and Pediococcus acidilactici CECT 7483 is provided. The probiotic composition is useful in treating, preventing, or ameliorating CO VID-19, and other infectious diseases. It is also useful in enhancing the immune response.

MIXTURE FOR TREATMENT OF RESPIRATORY ILLNESSES

Absstract of: US2024226185A1

For the purpose of treating a patient having Covid-19 (or another respiratory illness), a composition is formed from a pair of solutes via batch processing for inhalation by a person suffering from a respiratory illness. A first solute is formed by dissolving menthol crystals into high content ethanol. A second solute is formed by dissolving Manuka honey into normal saline. After mixing the two solutes separately, the two solutes may be mixed together and the final mixture may be administered to a human person via a nebulizer.

EZRIN PEPTIDE 1 FOR USE IN A METHOD OF TREATING COVID-19

Absstract of: US2024226231A1

The present invention relates to Ezrin peptide 1 and/or an analogue thereof for use in a method of treating COVID-19 and for use in a method of treating post COVID-19 syndrome.

IMMUOGENIC COMPOSITIONS OF MUTANT SARS-COV-2 N PROTEIN AND GENE AND METHODS OF USE THEREOF

Absstract of: US2024226280A1

Compositions and methods for generating an immune response to fight against viral infections such as SARS-CoV-2 are provided. The disclosed compositions and methods are based on the discovery of the three consecutive SNPs (G28881A, G28882A, G28883C) underlying the R203K/G204R mutation in the SARS-CoV-2 N protein, associated with increased immune system response when expressed in cells. The immune responses that can be upregulated by the disclosed compositions include antibody production and/or upregulation of immune related genes that are generally involved in host defense against viral and bacterial infections, for example, increased expression of one or more genes including, but not limited to SHFL, MX1, AMD9L, TRIM22, TRIM14, EIF2 AK2, etc.The compositions include a peptide of the SARS-CoV-2 N-protein including the R203K/G204R mutation, a fragment thereof, or a nucleic acid encoding the same.The compositions are administered to a subject in need thereof to elicit an immune response in the subject.

ORAL VACCINE VIA DENTAL BACTERIA AND EMITTED PEPTIDES TO PREVENT COVID-19 INFECTION

Absstract of: US2024226281A1

Disclosed is a pharmaceutical composition to prevent transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pharmaceutical composition comprising: genetically modified bacteria; sequences of small peptides; and pharmaceutical excipients, wherein the genetically modified oral bacteria are modified to translate, produce, and emit the sequences of small peptides which neutralize SARS-CoV-2 against COVID-19, wherein transgenic technology is used to modify the genetically modified oral bacteria to add genes in genetically modified oral bacteria that are transcribed to produce small peptides from the sequences of small peptides so added, wherein the sequences of small peptides show extreme binding and neutralization to SARS-CoV-2 but not to host proteins or processes, and wherein the pharmaceutical excipients aid the oral and/or nasal administration of the pharmaceutical composition.

COMPOSITIONS AND METHODS OF MRNA VACCINES AGAINST NOVEL CORONAVIRUS INFECTION

Absstract of: US2024226275A1

Provided herein is a ribonucleic acid (RNA) encoding a spike (S) protein or an immunogenic fragment thereof of a severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) comprising at least one non-naturally occurring amino acid mutation. In some embodiments, the S protein is derived from a delta variant. Additionally provided are relevant polynucleotides, vectors, cells, compositions, kits, production methods and methods of use.

COMPOSITIONS AND METHODS FOR MUCOSAL VACCINATION AGAINST SARS-COV-2

Absstract of: US2024226276A1

Disclosed are peptides comprising a monomeric Fc fragment of an immunoglobulin recognized by a FcRn; SARS-CoV-2 antigen; and a trimerization domain. Disclosed are peptide complexes comprising three peptides, wherein each of the three peptides comprises a monomeric Fc fragment of an immunoglobulin recognized by a FcRn; SARS-CoV-2 antigen; and a trimerization domain. Disclosed are compositions comprising any of the disclosed peptides or peptide complexes. Disclosed are methods for eliciting a protective immune response against SARS-CoV-2 comprising administering to a subject an effective amount of one or more of the compositions disclosed herein. Disclosed are methods of treating a subject exposed to SARS-CoV-2 or at risk of being exposed to SARS-CoV-2 comprising administering to a subject an effective amount of one or more of the compositions disclosed herein.

METHOD OF CONTROLLING SYMPTOMS RELATING TO COVID-19

Absstract of: US2024225811A1

A method of controlling symptoms relating to COVID-19 is provided. A filter is placed in a vein of a patient. The filter is placed between a heart and a palisading longitudinal esophageal vessel (PLEV) at a pharyngoesophageal junction (PEJ).

INACTIVATED VACCINES & NUCLEIC ACID APTAMER THERAPEUTICS DERIVED THEREFROM

Absstract of: US2024229007A1

Methods for producing dry thermostable inactivated vaccines with improved inactivation/killing without compromising antigenicity are disclosed. The methods provide for microbes to be irradiated with an ionizing radiation dose above 24 kGy without compromising the integrity of useful epitopes. To achieve enhanced inactivation, microorganisms (virions, bacterium, fungi, etc.) are first immobilized in a dry glassy matrix, then subsequently irradiated at elevated radiation dose while immobilized in the glass. Aptamers can be isolated from the inactivated microbes, such as inactivated SARS-COV-2, and modified or developed as therapeutics for neutralizing infectious disease. Additionally, non-neutralizing aptamers can be combined to produce an enhanced vaccine.

ANTI-VIRAL AND ANTI-TUMORAL COMPOUNDS, AND USES THEREOF

Absstract of: US2024228521A1

Disclosed herein are 3, 4-didehydro- and 3′-deoxy-3, 4-didehydro-compounds, and pharmaceutical compositions thereof. The 3, 4-didehydro- and 3′-deoxy-3, 4-didehydro-compounds, and pharmaceutical compositions thereof may be used in methods of treating diseases including virus-induced diseases, cancer, autoimmune diseases, immune disorders, and bacterial-associated diseases or infections, or combinations thereof. Examples of viral-induced diseases include viral infections by RNA or DNA viruses, for example SARS-CoV-2, EBV, and BKV.

ANTIBODIES FOR THE TREATMENT AND PREVENTION OF COVID-19 AND EMERGING VARIANTS

Absstract of: US2024228594A1

The subject matter disclosed herein relates to a recombinant spike (S) protein from the B.1.351.2-7 variant of the SARS-CoV-2 virus, the DNA and RNA nucleotide sequences encoding the recombinant B.1.351.2-7 spike protein, and engineered antibodies that bind the B.1.351.2-7 spike protein and neutralize the B.1.351.2-7 virus.

Methods for Monoclonal Antibody Generation

Absstract of: US2024228595A1

The present disclosure provides a set of high-throughput methods for rapid and efficient identification and generation of monoclonal antibodies. Also provided are highly potent human and humanized monoclonal antibodies and antigen-binding fragments and bispecific antibodies which are capable of binding to a wild-type or variant SARS-COV-2 spike protein receptor-binding domain (RBD), isolated nucleic acids and expression vectors encoding the antibodies and antigen-binding fragments and bispecific antibodies, cells comprising the nucleic acids and/or expression vectors, and methods for detecting, diagnosing, and/or neutralizing SARS-COV-2 and for treating at least one sign or symptom of a condition, disorder, or disease caused by SARS-COV-2 infection, including COVID-19.

POLYPEPTIDE FOR RESISTING NOVEL CORONAVIRUS AND APPLICATION THEREOF

Absstract of: US2024228547A1

The present application relates to a polypeptide for preventing or treating a novel coronavirus and an application thereof. The polypeptide is P3 polypeptide and any one of P3-1 polypeptide, P3-2 polypeptide, P3-3 polypeptide, P3-4 polypeptide, and P3-5 polypeptide derived from the P3 polypeptide. The amino acid sequences of the P3 polypeptide, the P3-1 polypeptide, the P3-2 polypeptide, the P3-3 polypeptide, the P3-4 polypeptide, and the P3-5 polypeptide are respectively shown in SEQ ID NOs: 1-6. The polypeptide of the present application has a strong inhibitory effect on original strains and a plurality of variant strains of the novel coronavirus, and can be used for preparing a drug or a vaccine for preventing and/or treating diseases caused by the novel coronavirus. The polypeptide is expected to also have the potential of preventing and/or treating new variant strains appearing in the future and sarbecovirus.

INTERACTION OF SARS-COV-2 PROTEINS WITH MOLECULAR AND CELLULAR MECHANISMS OF HOST CELLS AND FORMULATIONS TO TREAT COVID-19

Absstract of: US2024226120A1

The present invention provides pharmaceutical compositions and methods of treating Covid-19 infectious disease. The present invention also provides pharmaceutical compositions and methods of prophylaxis or prophylactic treatment of Covid-19 infectious disease. The said methods involve administering compositions comprising therapeutically effective amount of Cannabidiol thereby causing enhancement/augmentation of innate immunity of the patient/mammal/human.

NOVEL COMPOUNDS WITH DUAL INHIBITION ACTIVITY AGAINST SARS-COV-2 CRITICAL ENZYMES RDRP, MPRO AND HUMAN TMPRSS2

Absstract of: US2024226128A1

Novel SARS-CoV-2 inhibitors with dual targeting activity against both the viral RdRp and Mpro and host TMPRSS2 protease for therapeutic formulations and methods for treating SARS-CoV-2 infections. The present disclosure, in some embodiments, provides novel compounds with dual targeting activity against SARS-CoV-2. The compounds selectively target the viral RdRp and Mpro enzymes and host TMPRSS2 protease.

ANTIVIRAL NUCLEIC ACID

Absstract of: US2024229035A1

An object of the present invention is to provide an antiviral nucleic acid, etc. against SARS-COV-2 SARS-COV-2, SARS-COV-1, or MERS-COV and/or a method for treating and/or preventing viral infection using the nucleic acid, etc. The present invention relates to, for example, an antiviral nucleic acid or a pharmaceutically acceptable salt or hydrate thereof targeting a sequence in at least one target region selected from the group consisting of 5′ UTR region, nsp3 region, 3C-like proteinase region, nsp9 region, RNA-dependent RNA polymerase region, helicase region, 3′-to-5′ exonuclease region, 2′-O-ribose methyltransferase region, S region including S1 region and S2 region, E region, M region, and N region in genomic RNA of SARS-COV-2, wherein the virus is SARS-COV-2, SARS-COV-1, or MERS-COV.

INFECTIOUS RECOMBINANT VESICULAR STOMATITIS VIRUS (RVSV) BEARING THE SPIKE GLYCOPROTEIN S OF SARS-COV-2 AND USES THEREOF

Absstract of: US2024229066A1

Provided herein are recombinant vesicular stomatitis virus (rVSV) or rVSV vector comprising nucleic acid encoding the spike glycoprotein S of SARS-COV-2, compositions comprising such vectors or viruses, as well as screening methods, diagnostic methods, prophylactic and therapeutic methods using such vectors or viruses.

REPLICATION-COMPETENT CONTROLLED HERPESVIRUSES EXPRESSING A SARS COV-2 ANTIGEN

Absstract of: US2024229065A1

The present disclosure relates to replication-competent controlled herpesviruses whose transient replication in an inoculation site of a subject can be activated by the delivery of an appropriate heat dose to the inoculation site region. In related recombinant viruses, activation requires delivery of a heat dose in the presence in the inoculation site of an effective concentration of a small-molecule regulator. The viruses are engineered to express an antigen from a SARS CoV-2 virus and are expected to induce strong and balanced immune responses against the SARS CoV-2 antigen in subjects to which they are administrated.

LIPID NANOPARTICLES AND METHODS OF USE

Absstract of: US2024229034A1

Provided herein are, inter alia, lipid nanoparticles, lipid nanoparticles comprising nucleic acids encapsulated therein, pharmaceutical compositions comprising lipid nanoparticles which comprise nucleic acids encapsulated therein, and methods of treating diseases, such as coronavirus infections (e.g., SARS-CoV-2, SARS-CoV-2, MERS-CoV), COVID, and MERS.

PAN-SPECIFIC CORONA VIRUS BINDERS

Absstract of: US2024228596A1

Compositions and binding agents specifically binding the Spike protein of Corona viruses via at least two different binding sites and potently neutralizing coronaviruses, in particular sarbecoviruses, such as SARS-COV-1 and SARS-COV-2. The compositions or agents specifically bind to epitopes of the Receptor binding domain (RBD) of the Spike protein wherein both epitopes are conserved over multiple clades of the sarbecoviruses, providing broadly neutralizing pan-specific antibody-based compositions, thereby reducing viral escape. Application and uses of these agents and compositions are disclosed.

PROTEASE INHIBITORS FOR TREATING OR PREVENTING CORONAVIRUS INFECTION

Absstract of: US2024228535A1

The present invention provides a compound of Formula Iwherein R1, R2, R3, R4, R5, R6, R7, and subscripts x and n are as described herein and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for the treatment, inhibition, or amelioration of one or more disease states that could benefit from inhibition of a coronavirus, including SARS-CoV, MERS-CoV and SARS-CoV-2. The compounds of this invention could further be used in combination with other therapeutically effective agents, including but not limited to, other drugs useful for the treatment of coronavirus infection. The invention furthermore relates to processes for preparing compounds of Formula I, and pharmaceutical compositions which comprise compounds of Formula I and pharmaceutically acceptable salts thereof.

ANTIBODY AND FUSION PROTEIN FOR TREATING CORONAVIRUSES AND USE THEREOF

Absstract of: US2024228592A1

The present invention provides an antibody and a fusion protein for treating coronaviruses and use thereof. The 6-HB interference polypeptide in the fusion protein of the present invention and a part of an antibody or an antigen-binding fragment work synergistically to prevent fusion of SARS-COV or SARS-COV-2 virus particles with cells, and mediate phagocytosis and clearance of the virus particles by immune cells.

ANTIBODY SPECIFIC TO SPIKE PROTEIN OF SARS-COV-2 AND USES THEREOF

Absstract of: US2024228591A1

The present disclosure relates to an antibody or antigen-binding fragment thereof that specifically binds to a spike protein of SARS-COV-2. The present disclosure also relates to a pharmaceutical composition, a method for treating and/or preventing diseases and/or disorders caused by a coronavirus in a subject in need thereof, and a method for detecting a coronavirus in a sample.

NEUTRALIZING ANTIBODIES AGAINST SARS-RELATED CORONAVIRUS

Absstract of: AU2022400238A1

The present invention relates to antibodies or antigen-binding fragments thereof against SARS-related coronavirus, pharmaceutical compositions comprising such antibodies or antigen-binding fragments thereof, a kit comprising such antibodies or antigen-binding fragments thereof, and the antibodies or antigen-binding fragments thereof and the pharmaceutical composition and the kit for use as a medicament, and in the treatment or prevention of a disease caused by SARS-related coronavirus.

TREATING LONG COVID-19 WITH UROLITHINS

Absstract of: WO2023031673A1

The invention provides methods useful for treating post-viral illness, including long COVID-19, in a subject afflicted therewith comprising administering to the subject an urolithin.

ANTIBODY THERAPIES FOR SARS-COV-2 INFECTION IN PEDIATRIC SUBJECTS

Absstract of: CA3230613A1

The instant disclosure provides methods of treating or preventing a SARS-CoV-2 infection in a pediatric subject, e.g., in a pediatric subject having or at risk for developing COVID-19, wherein the methods include administering an antibody, antigen-binding fragment, or composition comprising the same to a pediatric subject. Disclosed methods include prophylactic administration for preventing SARS-CoV-2 infection or transmission, as well as treatment of a pediatric subject having a SARS-CoV-2 infection. A SARS-CoV-2 infection (e.g., causing COVID-19) to be treated can be at any stage of infection and/or can result in any stage of disease, for example, mild, mild-to-moderate, severe, or critical.

HUMAN NEUTRALIZING ANTIBODIES AGAINST SARS-COV-2 SPIKE S2 DOMAIN AND USES THEREOF

Absstract of: WO2023035016A1

The disclosure is based, at least in part, on certain human monoclonal antibodies, or antigen binding fragments thereof, having unexpected broad neutralizing activities against SARS-CoV-2. The disclosed antibodies and/or antigen-binding fragments thereof are therapeutic agents for the treatment of SARS-CoV-2 infections and are suitable for use in therapeutic methods to protect individuals from SARS-CoV-2 infections.

ORAL VACCINE VIA DENTAL BACTERIA AND EMITTED PEPTIDES TO PREVENT COVID-19 INFECTION

Absstract of: CA3231809A1

Disclosed is a pharmaceutical composition to prevent transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the pharmaceutical composition comprising: genetically modified bacteria; sequences of small peptides; and pharmaceutical excipients, wherein the genetically modified oral bacteria are modified to translate, produce, and emit the sequences of small peptides which neutralize SARS-CoV-2 against COVID-19, wherein transgenic technology is used to modify the genetically modified oral bacteria to add genes in genetically modified oral bacteria that are transcribed to produce small peptides from the sequences of small peptides so added, wherein the sequences of small peptides show extreme binding and neutralization to SARS-CoV-2 but not to host proteins or processes, and wherein the pharmaceutical excipients aid the oral and/or nasal administration of the pharmaceutical composition.

METHODS AND KIT FOR DETERMINING THE ANTIBODY STATUS AND T-CELL IMMUNITY AGAINST SARS-COV-2

Absstract of: WO2023031437A1

The invention provides a kit and method for determining the antibody status, especially of neutralizing antibodies, against SARS-CoV-2 in a subject, said kit comprising: (i) a solid support having attached an immobilized protein at least on a surface area of said solid support, (ii) a soluble protein, and (iii) a detection system for detecting binding of the soluble protein to the immobilized protein.

Formulation of ear drops and methods for delivery thereof for treating upper respiratory infections

Absstract of: US12029814B1

Compound formulations and methods for preventing or treating upper respiratory virus infections, such as influenza, respiratory syncytia virus (RSV), SARS, and SARS-COV-2, in human and animal species are disclosed. The compounds may exhibit antiviral, antimicrobial, anti-inflammatory, or cytoprotective activities. Liquid formulations comprising one or more compounds may be administered into the outer canal of the ear for delivery to the nasal and oral cavities, nasopharynx, posterior pharynx and laryngopharynx, the primary sites of upper respiratory infections, located across the tympanic membrane (or eardrum) and eustachian tube, of the individuals infected with one or more upper respiratory viruses or other pathogens. Methods to facilitate trans-tympanic membrane translocation of the compounds by thermal, electrical or electromagnetic impulse, manual or mechanical muscle contraction or stimulation of muscles, nerves or tissues proximate to the eardrum are disclosed.

NON-VIRAL DNA VECTORS EXPRESSING ANTI-CORONAVIRUS ANTIBODIES AND USES THEREOF

Absstract of: US2024216535A1

The application describes methods and compositions comprising ceDNA vectors useful for the expression of anti-CoV-2 S antibodies and antigen-binding fragments thereof in a cell, tissue or subject, and methods of treatment of COVID-19 with said ceDNA vectors.

PHARMACEUTICAL COMBINATION FOR THE TREATMENT OF THE RESPIRATORY INFECTION CAUSED BY SARS-COV-2

Absstract of: AU2022410715A1

The present invention relates to a composition comprising curcumin and arginine for use in the treatment of the respiratory infection caused by SARS-CoV-2 by means of the nasal administration thereof.

VALVED HOLDING CHAMBER WITH EXHALATION FILTER

Absstract of: US2024216623A1

A valved holding chamber is provided for the administration of drugs to a patient by inhalation from a metered dose inhaler having an exhalation filter on an exhalation pathway adapted to trapping aerosols and droplets in exhaled air. The exhalation filter may be angled at an approximately 45° angle away from the face of the patient. The exhalation filter prevents transmission of airborne diseases such as COVID-19 or influenza, or drug particles that could be sensitizing agents for caregivers or others in the patient's environment.

SARS-COV-2-SPECIFIC T CELLS AND METHODS OF TREATMENT USING THEM

Absstract of: US2024216507A1

The invention pertains to a method for preventing or treating SARS-CoV-2 infection by administering SARS-CoV-2 specific T cells which recognize particular peptide epitopes in SARS-CoV-2 spike (S), nucleocapsid (N), membrane, and envelope proteins.

-SARS-CoV-2 Pan-SARS-CoV-2 Vaccine Composition

Absstract of: KR20240103891A

본 발명은 범-CoV-2 백신 조성물에 관한 것이다. 본 발명의 백신 조성물은 범-사베코바이러스에서 보존성 높은 RBM의 위치 IIa 또는 S의 C-말단 줄기 나선(stem helix)을 포함하여 범-CoV-2 바이러스에 작용가능한 항체를 유도할 수 있으므로, 범-CoV-2 백신 조성물로 유용하게 사용될 수 있다.

VECTORED PROPHYLAXIS OF SARS-COV-2

Absstract of: US2024218392A1

Provided are composition and methods for use in prophylaxis or therapy of coronavirus infections. The compositions include an angiotensin-converting enzyme 2 (ACE2) ectodomain and a segment of an immunoglobulin Fc that is not an intact Fc region, and expression vectors encoding the same. The expression vectors include viral vectors.

SARS-COV-2 MPRO INHIBITOR COMPOUNDS

Absstract of: US2024217930A1

The invention described herein relates to compounds of Formula (1b):or a salt thereof, wherein R1, R1a, R2, R3 and R5 are defined herein, and their use in the treatment of SARS-CoV-2 and related viruses and disorders associated with SARS-CoV-2.

APTAMER-TYPE MULTI-WARHEAD COVALENT DRUG

Absstract of: US2024218376A1

The invention imparts new properties to nucleic acid aptamers, which may enhance its function as therapeutic drugs or the like. Also provided is a covalent drug having the new properties as an anti-SARS-COV-2 drug. Specifically, an aptamer-based multiwarhead covalent drug having multiple covalent binding warheads is provided. In particular, an aptamer-based multiwarhead covalent drug targeting SARS-COV-2 is provided. A pharmaceutical composition comprising the multiwarhead nucleic acid aptamer and a method of producing the multiwarhead nucleic acid aptamer are also provided.

Catalysis deactivated angiotensin-converting enzyme 2 (ACE2) variants and their uses

Absstract of: US2024218343A1

Angiotensin-converting enzyme 2 (ACE2) has been confirmed as a specific receptor for several β group coronaviruses include severe respiratory syndrome (SARS) coronavirus (SARS-CoV-1) and recently the causative agent for the World pandemic CoVID-19, SARS-CoV-2, and low pathogenic coronavirus of HCoV-NL63, a member in α-coronavirus group. Viral spike protein (S) of viral envelope is confirmed to bind to ACE2 as viral receptor to start a virus replication cycle. The present invention provides ACE2 and its mutants or variants, the viral or non-viral vectors thereof. Methods of treatment of viral infection of a human subject by using such mutants or variants are also provided.

NUCLEOCAPSID-SPECIFIC ANTIBODIES AND METHODS FOR THE TREATMENT AND PREVENTION OF SARS-COV-2 INFECTION THEREWITH

Absstract of: US2024218056A1

Provided herein are compositions and methods for the treatment and/or prevention of SARS-COV-2 infection, and symptoms and conditions associated therewith (e.g., COVID-19). In particular, provided herein are nucleocapsid-specific antibodies and methods of use thereof therapeutically or prophylactically to enhance the clearance of SARS-COV-2 infection from a subject.

PEPTIDES INHIBITING COVID-19

Absstract of: US2024218020A1

Provided are novel peptides which can block the binding interaction of novel coronavirus SARS-CoV-2 in mammals, specifically by inhibiting the interaction between the Spike SI protein of coronaviruses and the ACE2 receptor. The invention further relates to said peptides for use in treatment of COVID-19. Even further, the present invention relates to the peptides of the invention for use in inducing an immune response in a mammal by administration of said peptides.

TGF-Beta 1 INHIBITORS FOR PREVENTING AND TREATING SARS-COV-2

Absstract of: US2024218059A1

Prophylaxis and treatment method for SARS-CoV-2 infection are provided. Methods include administering a therapeutically effective amount of at least one TGF-β1 inhibitor to a subject at risk of contracting, or having a SARS-CoV-2 infection.

METHODS FOR THE DETERMINATION OF THE PREDISPOSITION FOR A SEVERE OR CRITICAL COURSE OF A COVID-19-DISEASE FROM A MILD OR MODERATE COURSE OF A COVID-19-DISEASE IN A SUBJECT

Absstract of: US2024219402A1

A method to determine the predisposition for a severe or critical course of a COVID-19-disease from a mild or moderate course of a COVID-19-disease in a subject. The method can be used to stratify a patient-group, diagnose a SASR-CoV-2-infection, predict the course of a COVID-19-disease in a subject, supervise the therapy of a subject with COVID-19 and/or monitor the efficacy of existing and novel therapeutic agents against COVID-19.

MOLECULAR SIGNATURES OF LONG-TERM COVID-19 AND TREATMENT THEREOF

Absstract of: US2024219385A1

In various embodiments, provided are immune response signatures that can be used for the diagnosis, monitoring, and treatment of long-term diseases and inflammatory disorders caused by viral infections. In some embodiments, the viral infection is SARS-CoV-2 infection. In some embodiments, the long-term disease is post-acute sequelae of SARS-CoV-2 infection (PASC).

NEUTRALIZING ANTI- SARS-COV-2 ANTIBODIES AND METHODS OF USE THEREOF

Absstract of: US2024218057A1

This disclosure provides novel neutralizing anti-SARS-COV-2 antibodies or antigen-binding fragments thereof. The disclosed anti-SARS-COV-2 antibodies constitute a novel therapeutic strategy in protection from SARS-COV-2 infections.

SERINE PROTEASE INHIBITORY EFFECTS OF HEALTH SUPPLEMENTS IN HUMAN CANCERUS CELL LINES

Absstract of: WO2024144461A1

The present invention relates generally to a method of detecting inhibitory effects of health supplements on serine protease in cell lines derived from human carcinomas. More, particularly, the present invention relates to inhibitory analysis of health supplementary products taken from market and/or chemically purified forms, in order to determine their competitors and/or inhibitory effects on serine protease such as trypsin so that these supplements can be used for the treatment once someone develop intense inflammatory reactions either due to infections like COVID-19 and/or pathological conditions such as cancer. The present invention further provides therapeutic applications for agents and/or condition which utilize human enzymatic system and/or cellular components for the development of pathological conditions.

METHOD FOR PROVIDING INFORMATION ON CORRELATION BETWEEN APPLICATION OF EPIDEMIC PREVENTION MEASURES AND ALLERGIC DISEASES

Absstract of: WO2024143580A1

The present invention relates to a method for providing information on the correlation between the application of epidemic prevention measures and allergic diseases, wherein the incidence of allergic diseases in a randomly selected population before and after the application of epidemic prevention measures, particularly the prevention measures against COVID-19, can be identified and compared to provide information that the application of epidemic prevention measures does not have a significant effect on the incidence of allergic diseases, which can be used to explore the reasons why the incidence of allergic diseases did not decrease during the COVID-19 pandemic.

NOVEL CORONAVIRUS IGA ANTIBODY DETECTION IMMUNOPROBE, PREPARATION METHOD THEREFOR AND USE THEREOF

Absstract of: WO2024139640A1

A novel coronavirus IgA antibody detection immunoprobe, a preparation method therefor and a use thereof. The novel coronavirus IgA antibody detection immunoprobe comprises colloidal gold, wherein the colloidal gold adsorbs an anti-human IgA antibody protein or a new coronavirus spike protein. A novel coronavirus IgA antibody detection test strip comprises a bottom plate (7), and a sample pad (1), a gold pad (2), a chromatography membrane (5), and a water absorption pad (6) which are provided on the bottom plate (7) and arranged in sequence; the chromatography membrane (5) is a solid-phase nitrocellulose membrane composed of a test line (3) and a quality control line (4); the gold pad (2) is coated with an immunoprobe. When the immunoprobe coated on the gold pad (2) contains the anti-human IgA antibody protein, the test line (3) is coated with the new coronavirus spike protein; or when the immunoprobe coated on the gold pad (2) contains the new coronavirus spike protein, the test line (3) is coated with the anti-human IgA antibody protein; the quality control line (4) is coated with a quality control protein. The present invention is used for evaluating the level of IgA generated by nasal mucosa after a novel coronavirus nasal spray vaccine is inoculated.

COMPOSITIONS AND METHODS FOR COVID-19 TREATMENT

Absstract of: AU2023213185A1

Provided herein are compositions for use in treatment fibrosis and in treatment of COVID-19, preferably moderate COVID-19, comprising Compound (1), or a pharmaceutically acceptable salt thereof. Also provided herein are methods for treatment of COVID-19, preferably moderate COVID-19 comprising administering to a patient in need thereof an amount of between 10 mg/day and 30 mg/day, of Compound (1).

NEOGLYCOCONJUGATES AS VACCINES AND THERAPEUTIC TOOLS

Absstract of: US2024216491A1

Neoglycoconjugates as immunogens and therapeutic/diagnostic tools are described herein. The neoglycoconjugates are produced by conjugating a carbohydrate antigen intermediate to a free amine group of a carrier material (e.g., carrier protein). The intermediate comprises a linker having a first end and a second end, the first end being conjugated to a carbohydrate antigen via a thio ether bond and the second end comprising a functional group reactable with a free amine group. Following coupling, the carbohydrate antigen becomes covalently bound to the carrier material via an amide, a carbamate, a sulfonamide, a urea, or a thiourea bond, thereby producing the neoglycoconjugate. Applications of the neoglycoconjugates as antigens, immunogens, vaccines, and in diagnostics are also described. Specifically, the use of (neo)glycoconjugates as vaccine candidates and other therapeutic tools against cancers, viruses such as SARS-CoV-2, and other diseases characterized by expression of aberrant glycosylation are also described.

BROMELAIN PROTEASE, BROMELAIN, JACALIN-LIKE LECTIN, EXTRACT FROM THE STEM AND/OR THE FRUIT OF A PINEAPPLE PLANT, COMBINATION PREPARATION, BROMELAIN PROTEASE INHIBITOR, PROTEIN/PROTEASE MIX, AND GLYCATED BROMELAIN PROTEIN FORMED BY EXOGENOUS NON-ENZYMATIC GLYCATION, FOR USE IN THE TREATMENT OR PROPHYLAXIS OF VIRUS INFECTIONS CAUSED BY CORONAVIRUSES IN A HUMAN OR ANIMAL

Absstract of: US2024216484A1

The present invention addresses the problem of indicating active-ingredient classes which can treat virus diseases caused by coronaviruses in a human or animal. Said treatment includes the acute treatment of an already existing virus disease and the prophylaxis of same. The present invention relates to a bromelain protease, bromelain, jacalin-like lectin, extract from the stem and/or the fruit of a pineapple plant, combination preparation, bromelain protease inhibitor, protein/protease mix, and glycated bromelain protein formed by exogenous non-enzymatic glycation, for use in the treatment or prophylaxis of virus infections caused by coronaviruses in a human or animal.

THIONUCLEOSIDES AS ANTIVIRAL AGENTS

Absstract of: US2024216413A1

Compounds, compositions and methods for preventing, treating or curing a coronavirus infection in human subjects or other animal hosts. In one embodiment, the compounds can be used to treat an infection with a severe acute respiratory syndrome virus, such as human coronavirus 229E, SARS, MERS, SARS-CoV-1, OC43, and SARS-CoV-2. In another embodiment, the methods are used to treat a patient infected with a Flavivirus, Picornavus, Togavirus, or Bunyavirus.

STRAINS OF PROBIOTIC BACTERIA FOR USE IN A PREVENTIVE METHOD OF TREATMENT OR IN AN ADJUVANT METHOD OF TREATMENT OF VIRAL RESPIRATORY INFECTIONS

Absstract of: US2024216449A1

The present invention relates to specific and selected strains of bacteria and compositions thereof for use in the treatment of viral respiratory tract infections, preferably coronavirus viral infections, such as severe acute respiratory syndrome by coronavirus (COVID-19).

METHODS AND USES OF PROTEIN DISULFIDE ISOMERASE INHIBITORY COMPOUNDS

Absstract of: US2024216365A1

Compositions and methods involving protein disulfide isomerase (PDI) inhibitors, such as protein disulfide isomerase A3 (PDIA3) inhibitory compounds, for human coronavirus, such as severe acute respiratory syndrome (SARS) virus (e.g., SARS-CoV-2), therapies are disclosed herein.

PLPRO INHIBITORS

Absstract of: AU2022413258A1

Provided herein are novel compounds (e.g., Formula X or Y), pharmaceutical compositions, and methods of using the same. The compounds herein can typically inhibit PLpro activities. The compounds herein can also be used for treating a variety of diseases or disorders, such as viral infection caused by a coronavirus such as SARS-CoV- 2.

DETECTION OF SARS-COV-2

Absstract of: AU2022346926A1

A molecularly imprinted polymer comprises at least one recognition site that is complementary to a template molecule consisting of an amino acid sequence corresponding to a subsequence of the receptor binding domain of SARS-CoV-2 spike protein, wherein the amino acid sequence is no more than 50 amino acids in length and comprises a sequence selected from (i) NSNNLDSKVGG, (ii) NYNYLYRLFRKS, (iii) YRLFRKSNLKPF, (iv) STEIYQAGSTPC, (v) CNGVEGFNCYF,(vi) GSTPCNGVEGF, (vii) CYFPLQSYGFQP, (viii) GFQPTNGVGYQ and (ix) LQSYGFQPTNG. A method of preparing the molecularly imprinted polymer is also provided. Conjugates comprising the molecularly imprinted polymer and a fluorophore are also provided as are compositions containing the molecularly imprinted polymer and conjugates of the invention. The molecularly imprinted polymer, conjugate and compositions can be used in the detection of SARS-CoV-2.

TREATMENT OF COVID-19

Absstract of: AU2022334112A1

Provided herein are compositions useful for the treatment of COVID-19.

A COMPOSITION FOR MANAGEMENT OF COVID-19 AND ASSOCIATED

Absstract of: UA128422C2

The present disclosure provides a composition that may find utility in management of COVID-19. The inventors of the present disclosure surprisingly observed that ingredients of the composition of the present disclosure exhibit functional synergy therebetween, wherein the composition prevents virus replication and/or Virus entry into human cells, either wholly or in part, while modulating immune response of the patient. Hence, the composition of the present disclosure holds potential for wide spread usage in management of COVID-19, either alone or in combination with other preventive or palliative/symptomatic or therapeutic strategies.

Conserved region T cell vaccines for coronavirus and methods of use

Absstract of: US12023376B1

Immunogenic compositions and methods of their use in eliciting immune responses to coronaviruses, such as SARS-CoV-2 are provided.

Coronavirus neutralizing humanized antibodies and uses thereof

Absstract of: US12024551B1

The present disclosure relates to an isolated or purified antibody, or a fragment thereof, having a binding domain that binds to a coronavirus (e.g., SARS-COV-2) or a portion thereof. In other embodiments, the antibody includes a binding domain that competes with binding to angiotensin converting enzyme 2 (ACE2) or a portion thereof. Methods of using such antibodies are also described herein, such as methods of treating or delaying the progression of a disease associated with a coronavirus.

COVID-19 Food manufacturing method to improve sarcopenia caused by infection with COVID-19 or as a side effect of vaccination

Nº publicación: KR20240100778A 02/07/2024

Applicant:

김유학